Supplement Tables

Title: Optimal Duration of Dual Antiplatelet Therapy for Minor Stroke Within 72 Hours of Symptom Onset: A Prospective Cohort Study

List of Supplemental Tables

.

Liu T, *et al. Stroke Vasc Neurol* 2024;0:1–12. doi: 10.1136/svn-2023-002933

sTable 1 Summary of All Type and Doses of Therapies.		
Type/dose	Dose	n./N total (%)
Single antiplatelet therapy	Aspirin monotherapy (100-300mg/day)	961 (32.3)
	Clopidogrel* monotherapy (75mg/day)	202 (6.8)
Dual antiplatelet therapy	Aspirin 100-300mg/day + Clopidogrel (first day used load-dose 300mg, followed by 75 mg/day)	1170 (39.3)
	Aspirin 100-300mg/day + Clopidogrel (followed by 75 mg/day)	644 (21.6)
Clopidogrel* indicated all doses on the first day (75mg/daily, or first day used load-dose 300mg, followed by 75 mg/day).		

sTable 2. Distributions of the Baseline Characteristics in Patients Stratified by Treatment Group before and after Adjustment.																
	Crude				IPTW				SMRW				PSM			
Characteristics	SAPT	DAPT	P Value #	ASD †	SAPT	DAPT	P Value #	ASD †	SAPT	DAPT	P Value #	ASD †	SAPT	DAPT	P Value #	ASD †
N, (Mean ± SD)/%	1163	1814			1188	1767			1208	1801			732	732		
Age, y	64.9±12.7	59.7±11.0	<.001	.35	61.2±13.1	61.4±11.1	.89	.007	61.4±12.8	61.6±10.9	.69	.01	61.9±12.7	64.4±11.1	.09	.07
Male	808 (69.5)	1375 (75.8)	<.001	.14	877 (73.8)	1295(73.3)	.75	.01	925 (76.5)	1364 (75.7)	.59	.02	537 (73.4)	522 (71.3)	.38	.046
BMI, kg/m^2	24.6±3.6	25.1±3.5	<.001	.16	24.9±3.9	24.9±3.4	.96	.004	25.1±4.0	25.1±3.5	.98	.003	24.8±3.7	24.8±3.4	.69	.02
SBP, mmHg	152.1±22.3	153.5±21.6	0.09	.06	152.7±22.6	152.4+22.0	.69	.01	153.0±22.8	153.4±21.6	.60	.02	152.1±22.0	152.7±22.6	.56	.03
DBP, mmHg	87.0±13.7	89.3±13.6	<.001	.17	87.9±14.0	88.2±13.7	.69	.02	88.5±14.1	89.3±13.63	.33	.06	87.9±13.9	87.5±(13.9	.61	.03
Risk factors, n (%)																

Smoking			<.001	.20			.32	.01			.260	.043			.497	.081
Never	618 (53.1)	802 (44.2)			550 (46.3)	828 (46.9)			510 (42.2)	797 (44.3)			345 (47.1)	357 (48.8)		
Previous	71 (6.1)	111 (6.1)			73 (6.2)	108 (6.1)			74 (6.2)	109 (6.1)			44 (6.0)	55 (7.5)		
Current	434 (37.3)	852 (47.0)			530 (44.7)	782 (44.2)			593 (49.1)	848 (47.1)			322 (44.0)	298 (40.7)		
Hypertension	726 (62.4)	1078 (59.4)	.10	.06	720 (60.6)	1064(60.2)	.83	.008	719 (59.5)	1070 (59.4)	.95	.002	445 (60.8)	447 (61.1)	.92	.006
Diabetes mellitus	325 (27.9)	467 (25.7)	.19	.05	314 (26.4)	459 (26.0)	.78	.01	308 (25.5)	462 (25.7)	.92	.005	203 (27.7)	203 (27.7)	1	<.001
Dyslipidemia	24 (2.1)	45 (2.5)	.46	.03	26 (2.2)	40 (2.3)	.89	.005	28 (2.4)	43 (2.4)	.90	.002	15 (2.0)	19 (2.6)	.49	.04
Previous AF	11 (0.9)	5 (0.3)	.02	.09	6 (0.5)	7 (0.4)	.66	.02	2 (0.2)	5 (0.3)	.53	.02	4 (0.5)	5 (0.7)	1	.02
Previous TIA	17 (1.5)	32 (1.8)	.53	.02	25 (2.1)	29 (1.6)	.36	.03	30 (2.5)	30 (1.7)	.53	.06	13 (1.8)	12 (1.6)	.84	.01
Ischemic stroke	311 (26.7)	365 (20.1)	<.001	.16	279 (23.5)	412 (23.3)	.92	.005	259 (21.4)	365 (20.3)	.12	.03	168 (23.0)	189 (25.8)	.20	.07
Previous PAD	11 (0.9)	13 (0.7)	.49	.03	9 (0.7)	15 (0.8)	.79	.01	7 (0.6)	13 (0.7)	.44	.02	7 (1.0)	8 (1.1)	.79	.01
Previous AM	22 (1.9)	26 (1.4)	.33	.04	22 (1.8)	29 (1.7)	.67	.01	22 (1.8)	25 (1.4)	.64	.03	11 (1.5)	12 (1.6)	.83	.01
Previous CAD	73 (6.3)	91 (5)	.14	.06	66 (5.6)	100 (5.6)	.90	.003	63 (5.2)	89 (4.9)	.35	.01	41 (5.6)	39 (5.3)	.82	.01
Previous ICH	42 (3.6)	22 (1.2)	<.001	.16	24 (2.0)	32 (1.8)	.68	.02	13 (1.0)	22 (1.2)	.74	.02	12 (1.6)	14 (1.9)	.69	.02
Previous GC	22 (1.9)	12 (0.7)	.002	.11	13 (1.1)	20 (1.1)	.92	.001	8 (0.6)	12 (0.7)	0.72	0.004	9 (1.2)	8 (1.1)	.81	.01
Medication																

history																
Antiplatelet agents	141 (12.1)	195 (10.7)	.32	.06	154 (13.0)	205 (11.6)	.27	.049	164 (13.6)	194 (10.8)	.03	.09	84 (11.5)	88 (12.0)	.87	.03
Anti-hypertensive	499 (42.9)	731 (40.3)	.33	.05	489 (41.2)	719 (40.7)	.79	.01	485 (40.1)	727 (40.4)	0.91	0.02	299 (40.8)	310 (42.3)	052	.06
Statins	98 (8.4)	126 (6.9)	.192	.06	105 (8.8)	142 (8.0)	.44	.03	110 (9.1)	126 (7.0)	.91	.08	60 (8.2)	60 (8.2)	1	<.001
Anit-diabetes	248 (21.3)	343 (18.9)	.21	.06	246 (20.7)	352 (19.9)		.03	245 (20.2)	341 (18.9)	.04	.06	160 (21.9)	159 (21.7)	.99	.003
Antiplatelet days	66.3± 34.6	34.1± 32.2	<.001	.97	45.4± 37.0	45.6± 36.3	.92	.005	32.5± 32.3	33.9± 32.14	.65	.05	53.9± 37.4	54.4± 37.0	.81	.01
Strength statin	573 (49.6)	1188 (65.9)	<.001	.33	751 (63.2)	1100 (62.2)	.59	.021	865 (71.6)	1186 (65.9)	.001	.12	447 (61.1)	491 (67.1)	.02	.13
Clinical evaluation, n (%)																
Baseline NIHSS score			.58	.02			.83	.011			.31	.06			.44	.04
0-3	948 (81.5)	1464 (80.7)			945 (79.6)	1414(80.0)			948 (78.4)	1414 (80.8)			587 (80.2)	575 (78.6)		
4-5	215 (18.5)	350 (19.3)			243 (20.4)	353 (20.0)			260 (21.6)	346 (19.2)			145 (19.8)	157 (21.4)		
Onset to arrival time			<.001	.17			.37	.004			.62	.02			.17	.07
0-24 hr	593 (51)	1077 (59.4)			623 (56.7)	997 (56.4)			728 (60.2)	1069 (59.4)			395 (54)	421 (57.5)		
24-72 hr	570 (49)	737 (40.6)			515 (43.3)	770 (43.6)			480 (39.8)	732 (40.6)			337 (46.0)	311 (42.5)		
Pre-stroke mRs			.07	.09			.49	.03			.25	.048			.005	.17
0	968 (83.2)	1565 (86.3)			1000 (84.2)	1504(85.1)			1025 (84.8)	1555 (86.3)			628 (85.8)	581 (79.4)		
1	161	207			153	220			148	205			85	126		

	(13.8)	(11.4)			(12.9)	(12.5)			(12.3)	(11.4)			(11.6)	(17.2)		
2	34 (2.9)	41 (2.3)			35 (2.9)	43 (2.4)			35 (2.9)	41 (2.3)			19 (2.6)	25 (3.4)		
ICAS			.001	.14			.79	.03			.40	.06			.46	.07
No	614 (52.8)	1073 (59.2)			659 (55.5)	994 (56.3)			692 (57.2)	1068 (59.3)			390 (53.3)	388 (53.0)		
Yes	497 (42.7)	687 (37.9)			480 (40.4)	709 (40.1)			470 (38.9)	680 (37.8)			319 (43.6)	312 (42.6)		
TOAST			.002	.14			.23	.04			.20	.08			.81	.052
LAA	373 (32.1)	526 (29)			383 (32.3)	544 (30.8)			391 (32.3)	521 (28.9)			244 (33.3)	250 (34.2)		
SVO	485 (41.7)	884 (48.7)			523 (44.0)	810 (45.8)			550 (45.5)	876 (48.6)			316 (43.2)	313 (42.8)		
OE	22 (1.9)	28 (1.5)			23 (1.9)	35 (2.0)			23 (1.9)	28 (1.6)			16 (2.2)	21 (2.9)		
UD	283 (24.3)	376 (20.7)			259 (21.8)	379 (21.4)			245 (20.3)	376 (20.9)			156 (21.3)	148 (20.2)		
New infarct*	697 (59.9)	945 (52.1)	<.001	.22	665 (56.0)	974 (55.1)	.67	.02	648 (53.6)	940 (52.2)	.44	.03	422 (57.7)	360 (49.2)	<.001	.19
Laboratory findings (Mean ± SD)																
LDL, mmol/L	2.6 ± 0.9	2.6 ± 0.8	.28	.04	2.6± 0.8	2.6± 0.8	.25	.01	2.7± 0.8	2.6± 0.8	.50	.04	2.6± 0.8	2.6± 0.8	.24	.06
TC, mmol/L	4.1± 1.1	4.2± 1.1	.18	.05	4.2± 1.1	4.2± 1.1	.89	.007	4.2± 1.1	4.2± 1.1	.40	.02	4.1± 1.1	4.1± 1.1	.98	.001
HCY, μmol/L	23.5± 21.2	24.2± 21.1	.42	.03	24.2± 22.4	24.0± 21.5	.29	.01	24.6± 23.1	24.2± 21.1	.40	.02	24.2± 22.8	23.3± 21.4	.46	.04
Cr, μmol/L	76.6± 42.6	73.7± 29.5	.03	.08	75.0± 31.5	74.5± 35.7	.63	.02	74.0± 21.9	73.7± 29.5	.30	.01	76.4± 44.7	74.1± 41.2	.31	.053
Urea, mmol/L	5.5±	5.7±	.69	.02	5.4±	5.6±	.43	0.02	5.4±	5.7±	.42	.03	5.5±	5.5±	.74	.02

	2.1	14.4			1.9	11.7			1.7	1.5			2.2	2.4		
INR	1.1± 0.4	1.1± 0.4	.93	.001	1.1± 0.3	1.1± 0.4	.24	.011	1.1± 0..2	1.1± 0.4	.51	.04	1.1± 0.2	1.1± 0.1	.88	.008
PLT, 109/L	214.6 ±66.0	219.3± 60.6	.045	0.07	218.5 ±67.0	218.5 ±60.1	.94	<.00 1	220.7 ±67.5	219.4 ±60.7	.42	.02	217.2 ±69.9	217.6± 60.4	.90	.007
WBC, 109/L	7.1± 2.2	7.2± 2.1	0.573	.02	7.3± 2.3	7.2± 2.2	.49	0.03 7	7.4± 2.3	7.2± 2.1	.001	.10	7.2± 2.2	7.4± 2.2	.07	.10

Abbreviations: AF, atrial fibrillation; ASD, absolute standardized difference; BMI, body mass index; CAD, coronary artery disease; Cr, creatinine; DBP, diastolic blood pressure; ESRS, Essen stroke risk score; GU, gastric ulcer; HCY, homocysteine; LAA, large-artery atherosclerosis; LDL, low-density lipoprotein; MI, myocardial infarction; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OE, stroke of other determined etiology; PAD, peripheral artery disease; PLT, platelet; PSM, propensity score matching; ICAS, intracranial atherosclerosis; ICH, intracranial hemorrhage; IS, ischemic stroke; INR, international standardized ratio; IPTW, inverse probability of treatment weighting; SBP, systolic blood pressure;; SMRW, standardized mortality ratio weight; SVO, small-vessel occlusion; TC, total cholesterol; TIA, transient ischemic attack; TOAST, Trial of Org 10172 in Acute Stroke Treatment; UD, stroke of undetermined etiology; and WBC, white blood cell.

*Indicated the image (CT or MRI) before using antiplatelet drugs.

#P values were calculated using Pearson $\chi 2$ test, Fisher exact test, Student t test, or the Wilcoxon rank-sum test, as appropriate.

†An ASD of >0.1 is considered a meaningful imbalance.

5

sTable 3 Distributions of the General Characteristics in Patients Stratified by Treatment Group and Duration of Dual Antiplatelet Therapy.

Characteristics	SAPT (n=1163)	DAPT			P* value	P** value
		Shorter Duration (n=305)	Short Duration (n=937)	Long Duration (n=572)		
Age, y (Mean ± SD)	64.9 ± 12.7	61.0 ± 11.3	59.3 ± 10.8	59.6 ± 11.1	.054	< .001
Male	808 (69.5)	223 (73.1)	715 (76.3)	437 (76.4)	.49	< .001
BMI, kg/m^2 (Mean ± SD)	24.6 ± 3.6	25.1 ± 3.5	25.2 ± 3.5	25.0 ± 3.4	.47	< .001
SBP, mmHg (Mean ± SD)	152.1 ± 22.3	153.8 ± 20.3	154.3 ± 21.4	152.0 ± 22.6	.14	.09
DBP, mmHg (Mean ± SD)	87.0 ± 13.7	90.1 ± 13.3	89.6 ± 13.3	88.4 ± 14.3	.12	< .001
Smoking, n (%)					.04	< .001

7

Never	618 (53.1)	136 (44.6)	413 (44.1)	253 (44.2)		
Previous	71 (6.1)	24 (7.9)	40 (4.3)	47 (8.2)		
Current	434 (37.3)	135 (44.3)	459 (49)	258 (45.1)		
Medical history, no. (%)						
Hypertension	726 (62.4)	180 (59)	552 (58.9)	346 (60.5)	.82	.10
Diabetes	325 (27.9)	74 (24.3)	235 (25.1)	158 (27.6)	.44	.19
Dyslipidemia	24 (2.1)	7 (2.3)	23 (2.5)	15 (2.6)	.95	.46
AF	11 (0.9)	1 (0.3)	3 (0.3)	1 (0.2)	1.00	.02
TIA	17 (1.5)	5 (1.6)	15 (1.6)	12 (2.1)	.76	.53
Previous IS	311 (26.7)	71 (23.3)	169 (18)	125 (21.9)	.06	< .001
PAD	11 (0.9)	1 (0.3)	5 (0.5)	7 (1.2)	.27	.50
MI	22 (1.9)	3 (1)	12 (1.3)	11 (1.9)	.52	.33
CAD	73 (6.3)	11 (3.6)	45 (4.8)	35 (6.1)	.24	.14
ICH	42 (3.6)	5 (1.6)	11 (1.2)	6 (1)	.78	< .001
GU	22 (1.9)	2 (0.7)	5 (0.5)	5 (0.9)	.74	.002
Medication history, n (%)						
Antiplatelet	141 (12.1)	34 (11.1)	79 (8.4)	82 (14.3)	.003	.3
Anti-hypertensive	499 (42.9)	130 (42.6)	354 (37.8)	247 (43.2)	.21	.33
Statins	98 (8.4)	20 (6.6)	54 (5.8)	52 (9.1)	.12	.19
Anti-diabetes	248 (21.3)	50 (16.4)	161 (17.2)	132 (23.1)	.03	.21
Antiplatelet days	66.3 ± 34.6	5.8 ± 3.0	17.6 ± 3.9	76.2 ± 24.7	< .001	< .001
Strength statin at admission	573 (49.6)	188 (62.0)	591 (63.3)	407(72.2)	< .001	< .001
Clinical evaluation, n (%)						
Baseline NIHSS score					.44	.58
0-3 points	948 (81.5)	239 (78.4)	765 (81.6)	460 (80.4)		
4-5 points	215 (18.5)	66 (21.6)	172 (18.4)	112 (19.6)		
Onset to arrival time					.29	< .001
0-24 hr	593 (51)	192 (63)	556 (59.3)	329 (57.5)		
24-72 hr	570 (49)	113 (37)	381 (40.7)	243 (42.5)		
Pre-mRs					.003	.07

0	968 (83.2)	260 (85.2)	835 (89.1)	470 (82.3)		
1	161 (13.8)	40 (13.1)	86 (9.2)	81 (14.2)		
2	34 (2.9)	5 (1.6)	16 (1.7)	20 (3.5)		
ICAS					.02	.001
No	614 (52.8)	186 (61)	582 (62.1)	306 (53.5)		
Yes	497 (42.7)	108 (35.4)	329 (35.1)	249 (43.5)		
TOAST Classification					< .001	.002
LAA	373 (32.1)	76 (24.9)	238 (25.4)	212 (37.1)		
SVO	485 (41.7)	151 (49.5)	479 (51.1)	254 (44.4)		
OE	22 (1.9)	6 (2)	11 (1.2)	11 (1.9)		
UD	283 (24.3)	72 (23.6)	209 (22.3)	95 (16.6)		
New infarct[#]	697 (59.9)	156 (51.1)	528 (56.4)	261 (45.6)	< .001	< .001
Laboratory findings ((Mean ± SD)						
LDL, mmol/L	2.6 ± 0.9	2.6 ± 0.8	2.6 ± 0.8	2.6 ± 0.9	.53	.28
TC, mmol/L	4.1 ± 1.1	4.1 ± 1.1	4.2 ± 1.0	4.2 ± 1.1	.61	.18
HCY, μmol/L	23.5 ± 21.2	25.5 ± 28.4	23.8 ± 19.3	24.1 ± 19.2	.49	.42
Cr, μmol/L	76.6 ± 42.6	72.7 ± 30.1	73.6 ± 17.1	74.3 ± 42.3	.73	.03
Urea, mmol/L	5.5 ± 2.1	5.2 ± 1.4	5.3 ± 2.0	6.6 ± 25.5	.19	.70
INR	1.1 ± 0.4	1.1 ± 0.2	1.1 ± 0.4	1.1 ± 0.6	.83	.93
PLT, 109/L	214.6 ± 66.0	216.0 ± 67.0	218.1 ± 58.6	223.1 ± 60.0	.17	.045
WBC, 109/L	7.1 ± 2.2	7.2 ± 2.2	7.0 ± 2.0	7.4 ± 2.4	.02	.57

Abbreviations: AF, atrial fibrillation; BMI, body mass index; CAD, coronary artery disease; Cr, creatinine; DBP, diastolic blood pressure; ESRS, Essen stroke risk score; GU, gastric ulcer; HCY, homocysteine; LAA, large-artery atherosclerosis; LDL, low-density lipoprotein; MI, myocardial infarction; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OE, stroke of other determined etiology; PAD, peripheral artery disease; PLT, platelet; ICAS, intracranial atherosclerosis; ICH, intracranial hemorrhage; IS, ischemic stroke; INR, international standardized ratio; SBP, systolic blood pressure; SVO, small-vessel occlusion; TC, total cholesterol; TIA, transient ischemic attack; TOAST, Trial of Org 10172 in Acute Stroke Treatment; UD, stroke of undetermined etiology; and WBC, white blood cell.

#Indicated the image on CT or MRI before using antiplatelet drugs.

* Indicated compared the general characteristics among three groups of different duration in DAPT group through Pearson $\chi 2$ test, Fisher exact test and ANOVA.

** Indicated compared the general characteristics between DAPT and SAPT groups using Pearson χ2 test, Fisher exact test, Student t test, or the Wilcoxon rank-sum test, as appropriate.

6

sTable 4. General Characteristics of Dual Antiplatelet Therapy and Single Antiplatelet in Patients with Short Duration.												
	Crude				IPTW				PSM			
Characteristics (Mean ±SD)/%	SAPT (n=1163)	DAPT (n=937)	P value#	ASD†	SAPT (n=1279)	DAPT (n=592)	P value#	ASD†	SAPT (n=342)	DAPT (n=342)	P value#	ASD†
Age, y	64.9±12.7	59.3±10.8	<0.001	0.47	61.5 ±13.2	60.7±11.05	0.25	0.07	64.1±13.0	58.3±11.9	<0.001	0.47
Male	808 (69.5)	715 (76.3)	<0.001	0.15	922 (72.1)	440 (74.2)	0.31	0.049	243 (71.1)	271 (79.2)	0.01	0.19
BMI, kg/m^2	24.6 ± 3.6	25.2 ± 3.5	<0.001	0.18	24.8 ±3.82	25.0 ±3.42	0.37	0.06	24.7±4.1	25.4±3.7	0.02	0.18
SBP, mmHg	152.1±22.3	154.3±21.4	0.02	0.10	153.1 ±22.5	153.2±21.5	0.15	0.004	151.1±21.5	153.1±21.9	0.23	0.09
DBP, mmHg	87.0±13.7	89.6±13.3	<0.001	0.20	87.9± 14.6	88.6±13.2	0.17	0.045	86.8±14.1	89.4±14.0	0.02	0.18
Smoking, n (%)			<0.001	0.24			0.23	0.07			0.09	0.20
Never	618 (53.1)	459 (49.0)			621(48.6)	269(45.5)			162 (47.4)	142 (41.5)		
Previous	71 (6.1)	40 (4.3)			64 (5.0)	28 (4.7)			18 (5.3)	10 (2.9)		
Current	434 (37.3)	438 (46.7)			559 (43.7)	278(47.0)			150 (43.9)	180 (52.6)		
Medical history, no. (%)												
Hypertension	726 (62.4)	552 (58.9)	0.10	0.07	774 (60.5)	349(59.0)	0.52	0.03	199 (58.2)	193 (56.4)	0.64	0.04
Diabetes	325 (27.9)	235 (25.1)	0.14	0.07	333 (26.0)	149 (25.1)	0.69	0.02	85 (24.9)	74 (21.6)	0.32	0.08
Dyslipidemia	24 (2.1)	23 (2.5)	0.55	0.03	26 (2.1)	14 (2.4)	0.64	0.02	8 (2.3)	10 (2.9)	0.63	0.04
AF	11 (0.9)	3 (0.3)	0.08	0.08	8 (0.6)	3 (0.5)	0.76	0.01	3 (0.9)	1 (0.3)	0.62	0.08
TIA	17 (1.5)	15 (1.6)	0.80	0.02	19 (1.5)	10 (1.7)	0.74	0.02	7 (2)	2 (0.6)	0.18	0.13
Previous IS	311 (26.7)	169 (18.0)	<0.001	0.21	286(22.4)	121(20.5)	0.35	0.047	84 (24.6)	58 (17)	0.01	0.19
PAD	11 (0.9)	5 (0.5)	0.28	0.049	9 (0.7)	3 (0.6)	0.62	0.02	2 (0.6)	2 (0.6)	1.0	<0.001
MI	22 (1.9)	12 (1.3)	0.27	0.05	19 (1.5)	9 (1.5)	0.95	0.001	8 (2.3)	5 (1.5)	0.40	0.06
CAD	73 (6.3)	45 (4.8)	0.15	0.06	67 (5.2)	28 (4.8)	0.64	0.02	15 (4.4)	13 (3.8)	0.70	0.03
ICH	42 (3.6)	11 (1.2)	<0.001	0.16	30 (2.4)	9 (1.5)	0.25	0.07	6 (1.8)	5 (1.5)	0.76	0.02
GU	22 (1.9)	5 (0.5)	0.006	0.12	15 (1.1)	6 (1.0)	0.76	0.02	6 (1.8)	3 (0.9)	0.51	0.08
Medication history, n (%)												
Antiplatelet	141 (12.1)	79 (8.4)	0.01	0.13	137 (10.7)	57 (9.7)	0.48	0.03	39 (11.4)	33 (9.6)	0.83	0.06

Anti-hypertensive	499 (42.9)	354 (37.8)	0.048	0.11	523 (40.8)	224(37.9)	0.08	0.06	127 (37.1)	125 (36.5)	0.54	0.09
Statins	98 (8.4)	54 (5.8)	0.047	0.11	96 (7.5)	41 (6.8)	0.65	0.03	29 (8.5)	23 (6.7)	0.54	0.08
Anti-diabetes	248 (21.3)	161 (17.2)	0.054	0.11	244(19.0)	105 (17.8)	0.92	0.04	63 (18.4)	48 (14)	0.27	0.12
Antiplatelet days	66.3 ± 34.6	17.6 ± 3.9	<0.001	1.98	40 ±36.87	18 ±3.83		0.84	15.0±8.0	20. ±1.4	<0.001	1.01
Strength statin	573 (49.6)	591 (63.3)	<0.001	0.28	726 (56.7)	377 (63.7)	0.005	0.14	220 (64.3)	263 (76.9)	<0.001	0.28
Clinical evaluation, n (%)												
Baseline NIHSS score			0.94	0.01			0.11	0.04			0.40	0.06
0-3 points	948 (81.5)	765 (81.6)			1046 (81.8)	426 (80.4)			265 (77.5)	274 (80.1)		
4-5 points	215 (18.5)	172 (18.4)			233 (18.2)	116 (19.6)			77 (22.5)	68 (19.9)		
Onset to arrival time							0.054	0.10			0.40	0.07
0-24 hr	570(49.0)	381 (40.7)	<0.001	0.17	680 (53.2)	343 (58.0)			188 (55)	199 (58.2)		
24-72 hr	593 (51.0)	556 (59.3)			599 (46.8)	249 (42.0)			154 (45)	143 (41.8)		
Pre-mRs			<0.001	0.17			0.44	0.04			0.30	0.12
0	968 (83.2)	835 (89.1)			1100 (86.0)	516 (87.2)			287 (83.9)	301 (88)		
1	161 (13.8)	86 (9.2)			145 (11.4)	62 (10.5)			44 (12.9)	32 (9.4)		
2	34 (2.9)	16 (1.7)			34 (2.6)	13. (2.2)			11 (3.2)	9 (2.6)		
ICAS			<0.001	0.20			0.82	0.048			0.56	0.08
No	615 (52.9)	582 (62.1)			756 (59.1)	356 (60.2)			189 (55.3)	203 (59.4)		
Yes	496 (42.6)	329 (35.1)			470 (36.7)	216 (36.5)			140 (40.9)	127 (37.1)		
TOAST			<0.001	0.21			0.65	0.08			0.27	0.15
LAA	373 (32.1)	238 (25.4)			350 (27.3)	156(26.3)			100 (29.2)	85 (24.9)		
SVO	485 (41.7)	479 (51.1)			588 (45.9)	288 (48.5)			148 (43.3)	160 (46.8)		
OE	22 (1.9)	11 (1.2)			19 (1.5)	13 (2.1)			13 (3.8)	7 (2)		
UD	283 (24.3)	209 (22.3)			323 (25.3)	136 (23.0)			81 (23.7)	90 (26.3)		
New infarct*	697 (59.9)	528 (56.4)	0.14	0.15	79 (6.2)	35 (5.8)	0.82	0.02	24 (11.0)	23 (10.8)	0.97	0.04
Laboratory findings ((Mean ± SD)												
LDL, mmol/L	2.6 ± 0.9	2.6 ± 0.8	0.48	0.03	2.6 ± 0.83	2.6 ± 0.8	0.85	0.03	2.6±0.8	2.7±0.8	0.65	0.04
TC, mmol/L	4.1 ± 1.1	4.2 ± 1.0	0.17	0.06	4.2 ±1.1	4.2 ± 1.1	0.98	0.03	4.2±1.1	4.2±1.0	0.78	0.02
HCY, μmol/L	23.5 ±21.2	23.8 ±19.3	0.77	0.01	23.4 ± 21.2	23.6± 19.1	0.68	0.01	24.1±22.2	23.8±18.5	0.89	0.01

Cr, μmol/L	76.6 ±42.6	73.6 ±17.1	0.04	0.09	75.1± 32.9	73.9±17.7	0.51	0.045	74.2±17.3	74.9±18.1	0.60	0.04
Urea, mmol/L	5.5 ± 2.1	5.3 ± 2.0	0.01	0.11	5.4 ± 1.9	5.3± 2.0	0.78	0.04	5.4±1.7	5.3±2.0	0.58	0.04
INR	1.1 ± 0.4	1.1 ± 0.4	0.81	0.008	1.1 ± 0.3	1.1± 0.3	0.07	0.02	1.1±0.1	1.1±0.1	0.051	0.15
PLT, 109/L	214.6±66.0	218.1±58.6	0.21	0.054	216.4±66.0	216.1±60.1	0.78	0.003	211.4±64.0	213.3±63.8	0.69	0.03
WBC, 109/L	7.1 ± 2.2	7.0 ± 2.0	0.39	0.04	7.0 ± 2.1	7.1± 2.1	0.50	0.04	7.3±2.3	7.2±2.2	0.55	0.046

Abbreviations: AF, atrial fibrillation; ASD, absolute standardized difference; BMI, body mass index; CAD, coronary artery disease; Cr, creatinine; DBP, diastolic blood pressure; ESRS, Essen stroke risk score; GU, gastric ulcer; HCY, homocysteine; LAA, large-artery atherosclerosis; LDL, low-density lipoprotein; MI, myocardial infarction; mRs, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OE, stroke of other determined etiology; PAD, peripheral artery disease; PLT, platelet; ICAS, intracranial atherosclerosis; ICH, intracranial hemorrhage; IS, ischemic stroke; INR, international standardized ratio; SBP, systolic blood pressure; SVO, small-vessel occlusion; TC, total cholesterol; TIA, transient ischemic attack; TOAST, Trial of Org 10172 in Acute Stroke Treatment; UD, stroke of undetermined etiology; and WBC, white blood cell.

*Indicated the image (on CT or MRI) before using antiplatelet drugs.

#P values were calculated using Pearson $\chi 2$ test, Fisher exact test, Student t test, or the Wilcoxon rank-sum test, as appropriate.

†An ASD of >0.1 is considered a meaningful imbalance.

7

sTable 5. General Characteristics of Dual Antiplatelet Therapy (C-A) and Single Antiplatelet in Patients with Shorter Duration.

	Crude				IPTW				PSM			
Characteristics	SAPT	DAPT	P value#	ASD†	SAPT	DAPT	P value#	ASD †	SAPT	DAPT	P value#	ASD†
N, (Mean ± SD)/%	1163	305			1232	97			171	171		
Age, y	64.9 ±12.7	61.0 ± 11.3	< .001	.33	64.1±12.7	62.9±11.4	.004	.10	64.7±13.0	62.6±11.0	.11	.17
Male	808 (69.5)	223 (73.1)	.22	.08	862 (70.0)	70 (72.7)	.65	.06	120 (70.2)	124 (72.5)	.63	.05
BMI, kg/m^2	24.6 ±3.6	25.1±3.5	.15	.15	24.7±3.5	24.9±3.5		.04	24.8±4.6	25.0±3.5	.73	.04
SBP, mmHg	152.1±22.3	153.8 ±20.3	.23	.08	153.9±23.2	152.7±20.7		.06	151.0±21.3	151.0±20.3	.98	.003

12

DBP, mmHg	87.0 ±13.7	90.1 ± 13.3	<.001	.24	88.2±14.8	88.2±13.3		.002	86.5±14.5	87.7±11.9	.42	.09
Smoking, n (%)			.054	.17			.51	.09			.43	.18
Never	618 (53.1)	136 (44.6)			614 (49.8)	45 (46.7)			79 (46.2)	75 (43.9)		
Previous	71 (6.1)	24 (7.9)			64 (5.2)	7 (7.2)			10 (5.8)	15 (8.8)		
Current	434 (37.3)	135 (44.3)			522 (42.3)	42 (43.1)			75 (43.9)	78 (45.6)		
Medical history, no. (%)												
Hypertension	726 (62.4)	180 (59)	.28	.07	769 (62.4)	55 (56.7)	.26	.12	99 (57.9)	100 (58.5)	.91	.01
Diabetes	325 (27.9)	74 (24.3)	.20	.08	328 (26.6)	26 (26.4)	.97	.003	38 (22.2)	40 (23.4)	.79	.03
Dyslipidemia	24 (2.1)	7 (2.3)	.80	.02	28 (2.3)	3 (2.6)	.61	.02	5 (2.9)	6 (3.5)	.76	.03
AF	11 (0.9)	1 (0.3)	.48	.08	10 (0.8)	1 (0.8)	.82	.003	2 (1.2)	1 (0.6)	1	.06
TIA	17 (1.5)	5 (1.6)	.79	.02	16 (1.3)	2 (2.5)	.53	.09	4 (2.3)	3 (1.8)	1	.04
Previous IS	311 (26.7)	71 (23.3)	.22	.08	330 (26.7)	23 (23.5)	.51	.08	40 (23.4)	43 (25.1)	.71	.04
PAD	11 (0.9)	1 (0.3)	.48	.09	9 (0.7)	1 (0.3)	.74	.06	1 (0.6)	1 (0.6)	1	<.001
MI	22 (1.9)	3 (1)	.26	.08	22 (1.8)	2 (1.7)	.84	.007	3 (1.8)	2 (1.2)	1	.049
CAD	73 (6.3)	11 (3.6)	.07	.12	65 (5.2)	4 (4.2)	.62	.05	8 (4.7)	6 (3.5)	.59	.06
ICH	42 (3.6)	5 (1.6)	.08	.12	39 (3.2)	2 (2.3)	.55	.05	3 (1.8)	3 (1.8)	.60	<.001
GU	22 (1.9)	2 (0.7)	.20	.11	19 (1.5)	1 (0.9)	.69	.06	3 (1.8)	2 (1.2)	.65	.049
Medication history, n (%)												
Antiplatelet	141 (12.1)	34 (11.1)	.65	.09	169 (13.7	13 (12.9)	.93	.08	19 (11.1)	23 (13.5)	.51	.07
Antihypertensive	499 (42.9)	130 (42.6)	.82	.02	524 (42.5)	38 (39.6)	.52	.08	66 (38.6)	71 (41.5)	.69	.09
Statins	98 (8.4)	20 (6.6)	.45	.11	107 (8.6)	8 (8.2)	.88	.07	12 (7.0)	15 (8.8)	.55	.07
Anti-diabetes	248 (21.3)	50 (16.4)	.07	.14	264 (21.5)	17 (17.5)	.37	.11	27 (15.8)	30 (17.5)	.66	.047
Antiplatelet days	66.3 ± 34.6	5.8 ± 3.0	<.001	2.47	50.3±40.4	6.5 ±2.9	<.001	1.53	9.3±5.1	7.81 ±1.8	<.001	.40
Strength statin	573 (49.2)	188 (62.0)	<.001	.25	612 (49.7)	56(58.1)	.13	.17	101 (59.1)	107 (62.6)	.51	.07
Clinical evaluation, n (%)												

Baseline NIHSS score			.21	.07			.64	.053			.34	.10
0-3 points	948 (81.5)	239 (78.4)			1002(81.4)	77 (79.3)			135 (78.9)	142 (83)		
4-5 points	215 (18.5)	66 (21.6)			230 (18.6)	20 (20.7)			36 (21.1)	29 (17)		
Onset to arrival time			<.001	.27			.48	.13			.15	.16
0-24 hr	593 (51)	192 (63)			711 (52.8)	57 (59.1)			94 (55)	107 (62.6)		
24-72 hr	570 (49)	113 (37)			581 (47.2)	40 (40.9)			77 (45)	64 (37.4)		
Pre-mRs			.43	.09			.73	.03			.73	.11
0	968 (83.2)	260 (85.2)			1025(83.2)	82 (84.3)			145 (84.8)	140 (81.9)		
1	161 (13.8)	40 (13.1)			176 (14.3)	13 (13.4)			21 (12.3)	27 (15.8)		
2	34 (2.9)	5 (1.6)			31 (2.5)	2 (2.4)			5 (2.9)	4 (2.3)		
ICAS			.04	.17			.56	.07			.77	.08
No	615 (52.9)	186 (61)			686 (55.6)	57 (59.0)			97 (56.7)	103 (60.2)		
Yes	496 (42.6)	108 (35.4)			493 (40.0)	36 (37.6)			64 (37.4)	60 (35.1)		
TOAST Classification			.06	.18			.85	.12			.69	.13
LAA	373 (32.1)	76 (24.9)			354 (28.7)	27 (28.0)			51 (29.8)	44 (25.7)		
SVO	485 (41.7)	151 (49.5)			537 (43.6)	45 (46.1)			80 (46.8)	80 (46.8)		
OE	22 (1.9)	6 (2)			24 (1.9)	3 (3.3)			5 (2.9)	4 (2.3)		
UD	283 (24.3)	72 (23.6)			317 (25.7)	22 (22.5)			35 (20.5)	43 (25.1)		
New infarct *	697 (59.9)	156 (51.1)	.02	.17	704 (57.1)	51 (53.0)	.38	.08	101 (59.1)	93 (54.4)	.38	.09
Laboratory findings ((Mean ± SD)												
LDL, mmol/L	2.6 ± 0.9	2.6 ± 0.8	.96	.003	2.6 ± 0.8	2.6 ± 0.9	.50	.02	2.6±0.83	2.6±0.80	.50	.07
TC, mmol/L	4.1 ± 1.1	4.1 ± 1.1	.98	.002	4.1±1.0	4.2±1.1	.47	.01	4.2±1.1	4.1±1.1	.59	.06
HCY, μmol/L	23.5 ± 21.2	25.5 ± 28.4	.19	.07	22.8 ± 21.5	24.8 ± 27.1	.59	.08	25.0±25.5	24.0±22.2	.71	.04
Cr, μmol/L	76.6 ± 42.6	72.7 ± 30.1	.13	.11	74.9±37.5	73.1±29.3	.61	.09	72.9±16.0	70.9±16.3	.24	.13

Urea, mmol/L	5.5 ± 2.1	5.2 ± 1.4	.01	.19	5.4±1.9	5.2±1.4	.79	.001	5.3±1.5	5.2±1.4	.46	.08
INR	1.1 ± 0.4	1.1 ± 0.2	.72	.02	1.1±0.4	1.1±0.2	.13	.07	1.1±0.1	1.1±0.2	.78	.03
PLT, 109/L	214.6±66.0	216.0 ±67.0	.75	.02	214.6±62.3	210.0±67.6	.49	.06	213.0±68.4	216.0±72.4	.69	.04
WBC, 109/L	7.1 ± 2.2	7.2 ± 2.2	.63	.03	7.1±2.1	7.2 ±2.2	.60	.01	7.2±2.3	7.2±2.1	.83	.02

Abbreviations: AF, atrial fibrillation; ASD, absolute standardized difference; BMI, body mass index; CAD, coronary artery disease; C-A, clopidogrel-aspirin; Cr, creatinine; DBP, diastolic blood pressure; ESRS, Essen stroke risk score; GU, gastric ulcer; HCY, homocysteine; LAA, large-artery atherosclerosis; LDL, low-density lipoprotein; MI, myocardial infarction; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OE, stroke of other determined etiology; PAD, peripheral artery disease; PLT, platelet; ICAS, intracranial atherosclerosis; ICH, intracranial hemorrhage; IS, ischemic stroke; INR, international standardized ratio; SBP, systolic blood pressure; SVO, small-vessel occlusion; TC, total cholesterol; TIA, transient ischemic attack; TOAST, Trial of Org 10172 in Acute Stroke Treatment; UD, stroke of undetermined etiology; and WBC, white blood cell.
*Indicated the image (CT or MRI) before using antiplatelet drugs.
#P values were calculated using Pearson χ2 test, Fisher exact test, Student t test, or the Wilcoxon rank-sum test, as appropriate.
†An ASD of >0.1 is considered a meaningful imbalance.

8

sTable 6. General Characteristics of Dual Antiplatelet Therapy (C-A) and Single Antiplatelet in Patients with Longer Duration.

	Crude				IPTW				PSM			
Characteristics	SAPT	DAPT	P value#	ASD†	SAPT	DAPT	P value#	ASD †	SAPT	DAPT	P value#	ASD†
N, (Mean ± SD)/%	1163	572			1165	562			471	471		
Age, y	64.9 ± 12.7	59.6 ± 11.1	<.001	.44	63.1±13.1	62.3±11.1	.12	.04	60.5± 12.1	60.4±11.0	.91	.008
Male	808 (69.5)	437 (76.4)	.003	.16	847 (72.7)	414 (73.6)	.67	.02	358 (76.0)	359 (76.2)	.94	.005
BMI, kg/m^2	24.6 ± 3.6	25.0 ± 3.4	.02	.12	24.7±3.60	25.0±3.21	.99	.002	25.03 (3.40)	24.89 (3.26)	.52	.04
SBP, mmHg	152.1±22.3	152.0 ± 22.6	.95	.005	151.9±22.52	152.2±21.7	.85	.01	151.8± 22.9	152.9±22.5	.43	.051
DBP, mmHg	87.0 ±	88.4 ± 14.3	.046	.10	87.5±13.7	88.4±	.67	.06	88.1± 13.9	88.3±14.4	.82	.02

15

	13.7					13.8						
Smoking, n (%)			.001	.20			.65	.04			.99	.02
Never	618 (53.1)	253 (44.2)			596 (51.2)	294 (52.2)			208 (44.2)	211 (44.8)		
Previous	71 (6.1)	47 (8.2)			74 (6.3)	33 (5.9)			35 (7.4)	36 (7.6)		
Current	434 (37.3)	258 (45.1)			463(39.7)	223(39.7)			218 (46.3)	214 (45.4)		
Medical history, no. (%)												
Hypertension	726 (62.4)	346 (60.5)	.44	.04	707(60.7)	353 (62.8)	.39	.04	290 (61.6)	280 (59.4)	.51	.04
Diabetes	325 (27.9)	158 (27.6)	.89	.02	318 (27.3)	159 (28.2)	.67	.02	144 (30.6)	130 (27.6)	.32	.07
Dyslipidemia	24 (2.1)	15 (2.6)	.46	.03	26 (2.2)	13 (2.2)	.92	.004	14 (3.0)	13 (2.8)	.85	.01
AF	11 (0.9)	1 (0.2)	.12	.10	8 (0.7)	3 (0.6)	.71	.01	0 (0.0)	1 (0.2)	1.00	.07
TIA	17 (1.5)	12 (2.1)	.33	.03	16 (1.4)	7 (1.2)	.82	.02	6 (1.3)	7 (1.5)	.78	.02
Previous IS	311 (26.7)	125 (21.9)	.03	.11	294 (25.2)	154 (27.3)	.34	.048	114 (24.2)	109 (23.1)	.70	.03
PAD	11 (0.9)	7 (1.2)	.59	.03	11 (1.0)	5 (0.9)	.91	.005	6 (1.3)	5 (1.1)	.76	.02
MI	22 (1.9)	11 (1.9)	.96	.01	21 (1.8)	11 (1.9)	.82	.008	10 (2.1)	10 (2.1)	1.00	<.001
CAD	73 (6.3)	35 (6.1)	.89	.02	81 (6.9)	30 (5.4)	.20	.06	27 (5.7)	26 (5.5)	.89	.009
ICH	42 (3.6)	6 (1)	.002	.17	33 (2.8)	33 (5.9)	.002	.15	9 (1.9)	6 (1.3)	.44	.05
GU	22 (1.9)	5 (0.9)	.11	.09	18 (1.5)	6 (1.1)	.43	.03	4 (0.8)	4 (0.8)	1.00	<.001
Medication history, n (%)												
Antiplatelet	141 (12.1)	82 (14.3)	.45	.07	143 (12.3)	73 (12.9)	.67	.02	68 (14.4)	63 (13.4)	.89	.03
Anti-hypertensive	499 (42.9)	247 (43.2)	.96	.03	499 (42.8)	260 (46.1)	.19	.07	209 (44.4)	201 (42.7)	.83	.04
Statins	98 (8.4)	52 (9.1)	.78	.04	99 (8.5)	50 (8.9)	.78	.02	48 (10.2)	44 (9.3)	.87	.03
Anti-diabetes	248 (21.3)	132 (23.1)	.52	.06	252 (21.6)	124 (22.1)	.07	.01	119	108 (22.9)	.69	.06

									(25.3)			
Antiplatelet days	66.3 ± 34.6	76.2 ± 24.7	<.001	.33	70.0±32.7	69.0±28.1	.46	.01	75.4±28.9	76.4±24.6	.58	.04
Strength statin	573 (49.6)	407(72.2)	<.001	.48	665 (57.1)	314 (56.5)	.64	.01	332 (70.5)	329 (69.9)	.83	.01
Clinical evaluation, n (%)												
Baseline NIHSS score			.58	.03			.73	.02			.68	.03
0-3 points	948 (81.5)	460 (80.4)			943 (80.9)	451 (80.3)			380 (80.7)	375 (79.6)		
4-5 points	215 (18.5)	112 (19.6)			222 (19.1)	111 (19.7)			91 (19.3)	96 (20.4)		
Onset to arrival time			.01	.13			.77	.02			.84	.01
0-24 hr	593 (51)	329 (57.5)			608 (52.2)	298 (53.1)			257 (54.6)	260 (55.2)		
24-72 hr	570 (49)	243 (42.5)			557 (47.8)	264 (46.9)			214 (45.4)	211 (44.8)		
Pre-mRs			.79	.04			.13	.09			.97	.02
0	968 (83.2)	470 (82.3)			975 (83.7)	454 (80.6)			392 (83.2)	393 (83.4)		
1	161 (13.8)	81 (14.2)			156 (13.4)	93 (16.6)			66 (14.0)	64 (13.6)		
2	34 (2.9)	20 (3.5)			34 (2.9)	16 (2.8)			13 (2.8)	14 (3.0)		
ICAS			.32	.08			.35	.06			.96	.02
No	615 (52.9)	306 (53.5)			621 (53.3)	288 (51.2)			252 (53.5)	249 (52.9)		
Yes	496 (42.6)	249 (43.5)			498 (42.7)	256 (45.5)			203 (43.1)	207 (43.9)		
TOAST Classification			.003	.19			.15	.08			.98	.03
LAA	373 (32.1)	212 (37.1)			398 (34.1)	212 (37.7)			171 (36.3)	175 (37.2)		
SVO	485 (41.7)	254 (44.4)			498 (42.7)	232 (41.2)			204 (43.3)	198 (42.0)		
OE	22 (1.9)	11 (1.9)			23 (1.9)	9 (1.6)			10 (2.1)	10 (2.1)		
UD	283 (24.3)	95 (16.6)			247 (21.2)	110 (19.5)			86 (18.3)	88 (18.7)		
New infarct*	697 (59.9)	261 (45.6)	<.001	.39	641 (55.0)	318 (56.6)	.54	.04	238 (50.5)	243 (51.6)	.87	.04
Laboratory findings ((Mean ± SD)												

LDL, mmol/L	2.6 ± 0.9	2.6 ± 0.9	.15	.08	2.6±0.9	2.6 ±0.8	.89	.02	2.7±0.9	2.6 ±0.8	.84	.01
TC, mmol/L	4.1 ± 1.1	4.2 ± 1.1	.23	.07	4.2±1.1	4.2 ±1.1	.92	.02	4.2±1.1	4.2 ±1.1	.82	.02
HCY, μmol/L	23.5 ± 21.2	24.1 ± 19.2	.59	.03	23.9±21.2	23.1±17.9	.62	.04	23.1±19.2	23.8±18.6	.59	.04
Cr, μmol/L	76.6 ± 42.6	74.3 ± 42.3	.29	.06	76.0±38.9	77.9±64.0	.89	.04	76.3±28.5	75.4±45.9	.73	.02
Urea, mmol/L	5.5 ± 2.1	6.6 ± 25.5	.15	.06	5.5 ±2.2	5.9±14.9	.33	.046	5.5±2.1	5.5±2.1	.74	.02
INR	1.1 ± 0.4	1.1 ± 0.6	.76	.02	1.1±0.41	1.1 ±0.5	.90	.008	1.1±0.20	1.1±0.5	.66	.03
PLT, 109/L	214.6 ±66.0	223.1 ± 60.0	.009	.14	218.7±67.8	217.3±59.9	.75	.02	221.7±67.7	221.3±59.5	.93	.005
WBC, 109/L	7.1 ± 2.2	7.4 ± 2.4	.04	.11	7.2±2.2	7.3±2.3	.61	.04	7.3±2.3	7.4±2.5	.73	.02

Abbreviations: AF, atrial fibrillation; ASD, absolute standardized difference; BMI, body mass index; CAD, coronary artery disease; C-A, clopidogrel-aspirin; Cr, creatinine; DBP, diastolic blood pressure; ESRS, Essen stroke risk score; GU, gastric ulcer; HCY, homocysteine; LAA, large-artery atherosclerosis; LDL, low-density lipoprotein; MI, myocardial infarction; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OE, stroke of other determined etiology; PAD, peripheral artery disease; PLT, platelet; ICAS, intracranial atherosclerosis; ICH, intracranial hemorrhage; IS, ischemic stroke; INR, international standardized ratio; SBP, systolic blood pressure; SVO, small-vessel occlusion; TC, total cholesterol; TIA, transient ischemic attack; TOAST, Trial of Org 10172 in Acute Stroke Treatment; UD, stroke of undetermined etiology; and WBC, white blood cell.
*Indicated the image (CT or MRI) before using antiplatelet drugs.
#P values were calculated using Pearson $\chi 2$ test, Fisher exact test, Student t test, or the Wilcoxon rank-sum test, as appropriate.
†An ASD of >0.1 is considered a meaningful imbalance.

sTable 7 Secondary Outcome Event Rates* of Single Antiplatelet Therapy and Dual Antiplatelet Therapy with Aspirin-Clopidogrel in Patients with Short Duration.

	Crude			IPTW			PSM		
	SAPT	DAPT	P value†	SAPT	DAPT	P value‡	SAPT	DAPT	P value§
Secondary outcome									
s-ICH									
No. of events	3	1		-	-		0	0	

90 days event rate (95CI%), %	0.3(0.0~0.5)	0.1(-0.1~0.3)	.43	-	-		-	-	
Myocardial infarction									
No. of events	2	3					0	2	-
90 days event rate (95CI%), %	0.2(-0.1~0.4)	0.3 (0.0~0.7)	.49	-	-		-	0.6(-0.2~1.5)	
Death									
No. of events	2	1		-	-		2	0	-
90 days event rate (95CI%), %	0.2 (0.0~0.5)	0.1(-0.1~0.3)	.69	-	-		0.6 (-0.2~1.5)	-	

Abbreviations: CI, Confidence interval; DAPT, dual antiplatelet therapy; IPTW, inverse probability of treatment weighting; PSM, propensity score matching; SAPT, single antiplatelet therapy; s-ICH, Symptomatic intracranial hemorrhage and TIA, Transient ischemic attack.

*Event rates were derived from Kaplan-Meier curves.

†P values calculated using log-rank tests.

‡P values calculated using IPTW log-rank tests.

§P values calculated using stratified log-rank tests.

sTable 8. Secondary Outcome HRs of Dual Antiplatelet Therapy Compared Single Antiplatelet Therapy According to the Analytical Methods Used in Patients with Standard Duration.

	Crude		Adjusted*		IPTW		PSM	
	HR (95%CI)	P value†	HR (95%CI)	P value†	HR (95%CI)	P value‡	HR (95%CI)	P value§
Secondary outcome								
s-ICH								
DAPT (vs. SAPT)	0.62 (0.06~6.84)	.69	11.61 (0~Inf)	.99	-	-	-	-
AM								
DAPT (vs. SAPT)	1.86 (0.31~11.15)	.49	0.79 (0.01~59.35)	.91	-	-	-	-
Death								
DAPT (vs. SAPT)	0.62 (0.06~6.84)	.69	27.83 (0~Inf)	1.00	-	-	-	-

Abbreviations: CI, Confidence interval; DAPT, dual antiplatelet therapy; IPTW, inverse probability of treatment weighting; PSM, propensity score matching; SAPT, single antiplatelet therapy; s-ICH, Symptomatic intracranial hemorrhage and TIA, Transient ischemic attack.

*Adjusted for the variables listed in Table 1.

†Conventional Cox proportional hazards models.
‡Weighted Cox proportional hazards models.
§Cox proportional hazards models within matched pairs.

sTable 9 Outcome Event Rates* of Single Antiplatelet Therapy and Dual Antiplatelet Therapy with Aspirin-Clopidogrel in Patients.

	Crude			IPTW			SMRW			PSM		
	SAPT	DAPT	P value †	SAPT	DAPT	P value ‡	SAPT	DAPT	P value ‡	SAPT	DAPT	P value §
Primary outcome												
All events												
No. of events	103	154		124	153		137	151		73	77	
90 days event rate (95CI%), %	8.9 (7.2-10.5)	8.5 (7.2-9.8)	.73	10.4 (8.7-12.2)	8.7 (7.3-10.0)	.10	11.3 (9.6-13.1)	8.4 (7.1-9.7)	.007	10.0 (7.8-12.1)	10.5 (8.3-12.7)	.74
Secondary outcomes												
IS												
No. of events	88	137		107	134		120	134		66	70	
90 days event rate (95CI%), %	7.6 (6.0-9.1)	7.6 (6.3-8.8)	.99	9.0 (0.74-10.6)	7.6 (6.3-8.8)	.17	9.9 (8.2-11.6)	7.4 (6.2-8.7)	.02	9.0 (6.9-11.1)	9.6 (7.4-11.7)	.67
TIA												
No. of events	8	9		11	10		13	9		3	4	
90 days event rate (95CI%), %	0.7 (0.2-1.2)	0.5 (0.2-0.8)	.50	0.9 (0.4-1.5)	0.6 (0.2-0.9)	.24	1.1 (0.5-1.7)	0.5 (0.2-0.8)	.07	0.4 (-0.1~0.9)	0.5 (0.0-1.1)	1
s-ICH												
No. of events	3	2		-	-		-	-		1	0	

90 days event rate (95CI%), %	0.3 (0.0-0.5)	0.1 (0.0-0.3)	.39	-	-		-	-		0.1 (-0.1-0.4)	0	1
AM												
No. of events	2	5		-	-		-	-		2	2	
90 days event rate (95CI%), %	0.2 (-0.1-0.4)	0.3 (0.0-0.5)	.71	-	-		-	-		0.3 (-0.1-0.7)	0.3 (-0.1-0.7)	1
Death												
No. of events	2	1		-	-		-	-		2	1	
90 days event rate (95CI%), %	0.2 (0.0-0.5)	0.1 (-0.1-0.2)	.57	-	-		-	-		0.3 (-0.1-0.7)	0.1 (-0.1-0.4)	1
Safety outcomes												
Sever bleeding												
No. of events	3	2	.39	-	-		-	-		1	0	
90 days event rate (95CI%), %	0.3 (-0.1-0.3)	0.1 (0.0-0.3)		-	-		-	-		0.1 (-0.1-0.4)	0	1
All ICH												
No. of events	30	33		25	31		24	33		18	16	
90 days event rate (95CI%), %	2.6 (1.7-3.5)	1.8	.16	2.1 (1.3-2.9)	1.8 (1.1-2.4)	.49	2.0 (1.2-2.8)	1.8 (1.2-2.5)	.76	2.5 (1.3-3.6)	2.2 (1.1-3.2)	.62
Any bleeding												
No. of events	78	143		77	127		79	129		48	59	
90 days event rate (95CI%), %	6.7 (5.3-8.1)	7.9 (6.6-9.1)	.24	6.5 (5.1-7.9)	7.2 (6.0-8.4)	.46	6.5 (5.1-7.9)	7.2 (6.0-8.4)	.51	6.9 (5.0-8.8)	8.1 (6.1-10.0)	.30
Abbreviations: CI, Confidence interval; DAPT, dual antiplatelet therapy; IPTW, inverse probability of treatment weighting; PSM, propensity score matching;												

SAPT, single antiplatelet therapy; s-ICH, Symptomatic intracranial hemorrhage; SMRW, standardized mortality ratio weight; and TIA, Transient ischemic attack.
*Event rates were derived from Kaplan-Meier curves.
†P values calculated using log-rank tests.
‡P values calculated using IPTW and SMRW log-rank tests.
§P values calculated using stratified log-rank tests.

sTable 10 HRs of Dual Antiplatelet Therapy Compared Single Antiplatelet Therapy According to the Analytical Methods Used.

	Crude		Adjusted*		IPTW		SMRW		PSM	
	HR (95%CI)	P value†	HR (95%CI)	P value†	HR (95%CI)	P value‡	HR (95%CI)	P value‡	HR (95%CI)	P value§
Primary outcome	0.96 (0.75~1.23)	.75	0.9 (0.68~1.21)	.50	0.83 (0.66~1.05)	.12	0.73 (0.58~0.92)	.007	1.07 (0.78~1.46)	.68
Secondary outcomes										
IS	1.01 (0.78~1.33)	.92	1.02 (0.75~1.38)	.92	0.84 (0.65~1.09)	.19	0.74 (0.58~0.95)	.02	1.09 (0.79~1.51)	.61
TIA	0.72 (0.28~1.87)	.50	0.83 (0.28~2.5)	.74	0.6 (0.26~1.4)	.24	0.45 (0.19~1.05)	.07	0 (0~Inf)	1.00
s-ICH	0.64 (0.09~4.55)	.66	1.09 (0.09~12.92)	.94	-	-	-	-	0 (0~Inf)	.99
AM	1.6 (0.31~8.26)	.57	1.77 (0.29~10.95)	.54	-	-	-	-	1 (0.14~7.12)	1.00
Death	0.32 (0.03~3.53)	.35	0 (0~Inf)	.99	-	-	-	-	0.5 (0.05~5.52)	.57
Safety outcomes										
Sever bleeding	0.64 (0.09~4.55)	.66	1.09 (0.09~12.92)	.94	-	-	-	-	0 (0~Inf)	.99
All ICH	0.73	.21	0.75	.31	0.8	0.40	0.91	.72	0.85	.62

	(0.44~1.2)		(0.43~1.31)		(0.48~1.35)		(0.54~1.53)		(0.44~1.62)	
Any bleeding	1.19 (0.9~1.57)	.22	1.08 (0.79~1.47)	.64	1.2 (0.91~1.59)	.19	1.19 (0.91~1.57)	.21	1.21 (0.83~1.74)	.30

Abbreviations: CI, Confidence interval; DAPT, dual antiplatelet therapy; IPTW, inverse probability of treatment weighting; PSM, propensity score matching; SAPT, single antiplatelet therapy; s-ICH, Symptomatic intracranial hemorrhage; SMRW, standardized mortality ratio weight; and TIA, Transient ischemic attack.

*Adjusted for the variables listed in Table S1.

†Conventional Cox proportional hazards models.

‡Weighted Cox proportional hazards models.

§Cox proportional hazards models within matched pairs.

sTable 11. Efficacy and Safety Outcome Event Rates* of Single Antiplatelet Therapy and Dual Antiplatelet Therapy with Aspirin-Clopidogrel in Patients with Shorter Duration.

	Crude			IPTW			PSM		
	SAPT	DAPT	P value†	SAPT	DAPT	P value‡	SAPT	DAPT	P value§
Primary outcome									
No. of events	103	31		105	9		20	11	
90 days event rate (95CI%), %	8.9 (7.2-10.5)	10.2(6.8-13.6)	.48	8.5(7.0-10.1)	9.3(3.4-15.2)	.79	11.7(6.8-16.6)	6.4(2.7-10.1)	.09
Secondary outcome									
Ischemic stroke									
No. of events	88	29		93	8		18	11	
90 days event rate (95CI%), %	7.6 (6.0-9.1)	9.5(6.2-12.8)	.27	7.5(6.1-9.0)	8.2(2.7-13.8)	0.80	10.5(5.9-15.2)	6.4(2.7-10.1)	0.174
TIA									
No. of events	8	1		7	0		2	0	
90 days event rate	0.7 (0.2-1.2)	0.3(-0.3-1.0)	.69	0.6(0.1-1.0)	0	.46	1.2(-0.5-2.8)	0	.50

(95CI%), %									
s-ICH									
No. of events	3	1		-	-		0	0	
90 days event rate (95CI%), %	0.3(0.0-0.5)	0.3(-0.3-1.0)	1	-	-		0	0	1
Myocardial infarction									
No. of events	2	0		-	-		0	0	
90 days event rate (95CI%), %	0.2(-0.1-0.4)	0	1	-	-		0	0	1
Death									
No. of events	2	0		-	-		0	0	
90 days event rate (95CI%), %	0.2 (0.0-0.5)	0	1	-	-		0	0	1
Safety outcome									
Sever bleeding									
No. of events	3	1		-	-		0	0	
90 days event rate (95CI%), %	0.3 (-0.1-0.3)	0.3(-0.3-1.0)	1	-	-		0	0	1
All intracranial hemorrhage									
No. of events	30	11		28	4		6	3	
90 days event rate (95CI%), %	2.6 (1.7-3.5)	3.6(1.5-5.7)	.33	2.3(1.4-3.1)	4.1(0.1-8.2)	.25	3.5(0.7-6.3)	1.8(-0.2-3.7)	.50
Any bleeding									
No. of events	78	39		76	10		15	18	
90 days event rate (95CI%）, %	6.7(5.3-8.1)	12.8(9.0-16.6)	<.001	6.1(4.1-16.5)	10.3(4.1-16.5)	.11	8.8(4.5-13.1)	10.5(5.9-15.2)	.62

Abbreviations: CI, Confidence interval; DAPT, dual antiplatelet therapy; IPTW, inverse probability of treatment weighting; PSM, propensity score matching; SAPT, single antiplatelet therapy; s-ICH, Symptomatic intracranial hemorrhage and TIA, Transient ischemic attack.
*Event rates were derived from Kaplan-Meier curves.
†P values calculated using log-rank tests.

‡P values calculated using IPTW log-rank tests.
§P values calculated using stratified log-rank tests.

sTable 12. HRs of Dual Antiplatelet Therapy Compared Single Antiplatelet Therapy According to the Analytical Methods Used in Patients with Shorter Duration.

	Crude		Adjusted*		IPTW		PSM	
	HR (95%CI)†	P value	HR (95%CI)†	P value	HR (95%CI) ‡	P value	HR (95%CI) §	P value
Primary outcome								
DAPT (vs. SAPT)	1.2 (0.8~1.8)	.37	0.86 (0.51~1.43)	.55	1.14 (0.57~2.29)	.70	0.57 (0.27~1.19)	.13
Secondary outcome								
Ischemic stroke								
DAPT (vs. SAPT)	1.32 (0.87~2.01)	.19	1.3 (0.83~2.03)	.25	1.18 (0.58~2.4)	.65	1.49 (0.84~2.64)	.17
TIA								
DAPT (vs. SAPT)	0.48 (0.06~3.81)	.49	0.27 (0.01~5.36)	.39	0.38 (0~29.9)	.66	0 (0~Inf)	.99
s-ICH								
DAPT (vs. SAPT)	1.91 (0.17~21.04)	.59	60.92 (0~Inf)	.93	-	-	-	-
AM								
DAPT (vs. SAPT)	0 (0~Inf)	.99	0 (0~Inf)	.99	-	-	-	-
Death								
DAPT (vs. SAPT)	0 (0~Inf)	.99	0.02 (0~Inf)	.99	-	-	-	-
Safety outcome								
Sever bleeding								
DAPT (vs. SAPT)	1.91 (0.17~21.04)	.59	60.92 (0~Inf)	.93	-	-	-	-
All ICH								
DAPT (vs. SAPT)	1.45 (0.73~2.91)	.29	1.72 (0.81~3.66)	.16	1.54 (0.5~4.71)	.45	1.85 (0.68~5)	.23
Any bleeding								
DAPT (vs. SAPT)	2 (1.36~2.94)	<.001	2.23 (1.48~3.36)	<.001	2.07 (1.13~3.79)	.02	2.53 (1.42~4.53)	.002

Abbreviations: CI, Confidence interval; DAPT, dual antiplatelet therapy; IPTW, inverse probability of treatment weighting; PSM, propensity score matching; SAPT, single antiplatelet therapy; s-ICH, Symptomatic intracranial hemorrhage and TIA, Transient ischemic attack.
*Adjusted for the variables listed in Table S4.
†Conventional Cox proportional hazards models.
‡Weighted Cox proportional hazards models.
§Cox proportional hazards models within matched pairs.

sTable 13 Efficacy and Safety Outcome Event Rates* of Single Antiplatelet Therapy and Dual Antiplatelet Therapy with Aspirin-Clopidogrel in Patients with Longer Duration.

	Crude			IPTW			PSM		
	SAPT	DAPT	P value†	SAPT	DAPT	P value‡	SAPT	DAPT	P value§
Primary outcome									
No. of events	103	59		102	58		37	56	
90 days event rate (95CI%), %	8.9 (7.2-10.5)	10.3(7.8-12.8)	.33	8.6(7.1-10.4)	10.3(7.8-12.8)	.29	7.9(5.4-10.3)	11.9 (9.0-14.8)	.04
Secondary outcome									
Ischemic stroke									
No. of events	88	55		88	51		32	52	
90 days event rate (95CI%), %	7.6 (6.0-9.1)	9.6(7.2-12.0)	.15	7.6(6.0-9.1)	9.1(6.7-11.5)	.28	6.8(4.5-9.1)	11.0 (8.2-13.9)	.02
TIA									
No. of events	8	2		7	3		2	2	
90 days event rate (95CI%), %	0.7 (0.2-1.2)	0.3(-0.1-0.8)	.51	0.6(0.2-1.0)	0.5(-0.1-1.1)	.86	0.4(-0.2-1.0)	0.4(-0.2-1.0)	1.000
s-ICH									
No. of events	3	0		-	-		2	0	
90 days event rate (95CI%), %	0.3(0.0-0.5)	0	.56	-	-		0.4(-0.2-1.0)	0	.49

Myocardial infarction									
No. of events	2	2		-	-		1	2	
90 days event rate (95CI%), %	0.2(-0.1-0.4)	0.3(-0.1-0.8)	.60	-	-		0.2(-0.2-0.6)	0.4(-0.2-1.0)	1
Death									
No. of events	2	0		-	-		0	0	
90 days event rate (95CI%), %	0.2 (0.0-0.5)	0	1	-	-		-	-	1
Safety outcome									
Sever bleeding									
No. of events	3	0		-	-		2	0	
90 days event rate (95CI%), %	0.3 (-0.1-0.3)	0	.56	-	-		0.4(-0.2-1.0)	0	.50
All intracranial hemorrhage									
No. of events	30	11		31	12		14	9	
90 days event rate (95CI%), %	2.6 (1.7-3.5)	1.9(0.8-3.1)	.39	2.7(1.7-3.6)	2.1(0.9-3.3)	.51	3.0(1.4-4.5)	1.9(0.7-3.2)	.82
Any bleeding									
No. of events	78	46		79	42		38	40	
90 days event rate (95CI%), %	6.7(5.3-8.1)	8.0(5.8-10.3)	.56	6.8(5.3-8.2)	7.5(5.3-9.7)	.58	8.1(5.6-10.5)	8.5(6.0-11.0)	.29

Abbreviations: CI, Confidence interval; DAPT, dual antiplatelet therapy; IPTW, inverse probability of treatment weighting; PSM, propensity score matching; SAPT, single antiplatelet therapy; s-ICH, Symptomatic intracranial hemorrhage and TIA, Transient ischemic attack.
*Event rates were derived from Kaplan-Meier curves.
†P values calculated using log-rank tests.
‡P values calculated using IPTW log-rank tests.
§P values calculated using stratified log-rank tests.

sTable 14. HRs of Dual Antiplatelet Therapy Compared Single Antiplatelet Therapy According to the Analytical Methods Used in Patients with Longer Duration.

	Crude		Adjusted*		IPTW		PSM	
	HR (95%CI)†	P value	HR (95%CI)†	P value	HR (95%CI) ‡	P value	HR (95%CI) §	P value
Primary outcome								
DAPT (vs. SAPT)	1.2 (0.87~1.65)	.27	1.3 (0.91~1.85)	.15	1.22 (0.88~1.68)	.24	1.64 (1.07~2.5)	.02
Secondary outcome								
Ischemic stroke								
DAPT (vs. SAPT)	1.31 (0.94~1.84)	.12	1.38 (0.95~2.01)	.09	1.28 (0.91~1.8)	.16	1.77 (1.13~2.78)	.01
TIA								
DAPT (vs. SAPT)	0.51 (0.11~2.39)	.39	0.86 (0.13~5.57)	.88	1 (0.14~7.13)	.99	0.5 (0.09~2.73)	.42
s-ICH								
DAPT (vs. SAPT)	0 (0~Inf)	.99	0.74 (0~Inf)	.99	-	-	0 (0~Inf)	.99
AM								
DAPT (vs. SAPT)	2.03 (0.29~14.43)	.48	0 (0~Inf)	.99	-	-	2 (0.18~22.18)	.57
Death								
DAPT (vs. SAPT)	0 (0~Inf)	.99	1.36 (0~Inf)	.99	-	-	-	-
Safety outcome								
Sever bleeding								
DAPT (vs. SAPT)	0 (0~Inf)	.99	0.74 (0~Inf)	.99	-	-	0 (0~Inf)	.99
All ICH								
DAPT (vs. SAPT)	0.77 (0.38~1.54)	.46	0.78 (0.36~1.69)	.53	0.77 (0.4~1.48)	.43	0.64 (0.28~1.47)	.29
Any bleeding								
DAPT (vs. SAPT)	1.21 (0.84~1.74)	.31	1.27 (0.86~1.88)	.24	1.13 (0.79~1.63)	.51	1.05 (0.67~1.63)	.84

Abbreviations:C-A, clopidogrel-aspirin; CI, Confidence interval; DAPT, dual antiplatelet therapy; IPTW, inverse probability of treatment weighting; PSM, propensity score matching; SAPT, single antiplatelet therapy; s-ICH, Symptomatic intracranial hemorrhage and TIA, Transient ischemic attack.

*Adjusted for the variables listed in Table S7.

†Conventional Cox proportional hazards models.

‡Weighted Cox proportional hazards models.

§Cox proportional hazards models within matched pairs.

sTable 15 General Characteristics of Patients Likely-CHANCE Population and no-RCT** Eligibility.

	Like-RCT population				No-RCT** Eligibility				
Characteristics	Total	SAPT	DAPT	P value[#]	Total	SAPT	DAPT	P value[#]	P value†
N, (Mean ± SD)/%	1342	466	876		1635	697	938		
Age, y	61.5 ± 11.6	65.0 ± 12.2	59.7 ± 10.8	<.001	61.9 ± 12.2	64.8 ± 13.0	59.7 ± 11.1	<.001	.44
Male	995 (74.1)	332 (71.2)	663 (75.7)	.08	1188 (72.7)	476 (68.3)	712 (75.9)	<.001	.36
BMI, kg/m^2	24.9 ± 3.6	24.7 ± 3.9	25.0 ± 3.5	.24	24.9 ± 3.4	24.4 ± 3.3	25.2 ± 3.4	<.001	.87
SBP, mmHg	153.2 ± 21.6	153.6 ± 22.2	153.0 ± 21.3	.63	152.6 ± 22.1	151.0 ± 22.3	153.8 ± 21.9	.01	.45
DBP, mmHg	88.5 ± 13.2	87.3 ± 13.5	89.2 ± 13.0	.01	88.3 ± 14.1	86.8 ± 13.9	89.4 ± 14.2	<.001	.64
Smoking, n (%)				.03				<.001	.41
Never	622 (46.3)	232 (49.8)	390 (44.5)		798 (48.8)	386 (55.4)	412 (43.9)		
Previous	90 (6.7)	28 (6)	62 (7.1)		92 (5.6)	43 (6.2)	49 (5.2)		
Current	587 (43.7)	185 (39.7)	402 (45.9)		699 (42.8)	249 (35.7)	450 (48)		
Medical history, no. (%)									
Hypertension	800 (59.6)	298 (63.9)	502 (57.3)	.02	1004 (61.4)	428 (61.4)	576 (61.4)	1.000	.32
Diabetes	349 (26)	131 (28.1)	218 (24.9)	.2	443 (27.1)	194 (27.8)	249 (26.5)	.56	.50
Dyslipidemia	34 (2.5)	9 (1.9)	25 (2.9)	.306	35 (2.1)	15 (2.2)	20 (2.1)	.98	.48
Atrial fibrillation	10 (0.7)	7 (1.5)	3 (0.3)	.038	6 (0.4)	4 (0.6)	2 (0.2)	.41	.16
TIA	22 (1.6)	4 (0.9)	18 (2.1)	.10	27 (1.7)	13 (1.9)	14 (1.5)	.56	.98
Previous IS	295 (22)	126 (27)	169 (19.3)	.001	381 (23.3)	185 (26.5)	196 (20.9)	.008	.39
PAD	14 (1)	4 (0.9)	10 (1.1)	.78	10 (0.6)	7 (1)	3 (0.3)	.11	.19

MI	21 (1.6)	9 (1.9)	12 (1.4)	.43	27 (1.7)	13 (1.9)	14 (1.5)	.56	.85
CAD	60 (4.5)	27 (5.8)	33 (3.8)	.09	104 (6.4)	46 (6.6)	58 (6.2)	.73	.03
ICH	32 (2.4)	20 (4.3)	12 (1.4)	<.001	32 (2)	22 (3.2)	10 (1.1)	.003	.42
Medication history, n (%)									
Antiplatelet	160 (11.9)	70 (15)	90 (10.3)	.02	176 (10.8)	71 (10.2)	105 (11.2)	.72	.52
Anti-hypertensive	553 (41.2)	206 (44.2)	347 (39.6)	.16	677 (41.4)	293 (42)	384 (40.9)	.29	.99
Statins	113 (8.4)	50 (10.7)	63 (7.2)	.03	111 (6.8)	48 (6.9)	63 (6.7)	.97	.22
Anti-diabetes	269 (20)	103 (22.1)	166 (18.9)	.31	322 (19.7)	145 (20.8)	177 (18.9)	.25	.93
Admission strength statin	801 (60.1)	212 (46.1)	589 (67.5)	<.001	960 (59)	361 (51.9)	599 (64.3)	<.001	.55
Clinical evaluation, n (%)									
Baseline NIHSS score				.56				.007	<.001
0-3 points	1342 (100)	378 (81.1)	699 (79.8)		1070 (65.4)	482 (69.2)	588 (62.7)		
4-5 points	0 (0)	88 (18.9)	177 (20.2)		565 (34.6)	215 (30.8)	350 (37.3)		
Onset to arrival time				.92				.11	<.001
0-24 hr	1342 (100)	450 (96.6)	845 (96.5)		328 (20.1)	127 (18.2)	201 (21.4)		
24-72 hr	0 (0)	16 (3.4)	31 (3.5)		1307 (79.9)	570 (81.8)	737 (78.6)		
Pre-mRs				.25				.28	.39
0	1146 (85.5)	388 (83.3)	758 (86.6)		1387 (84.8)	580 (83.2)	807 (86)		
1	167 (12.5)	67 (14.4)	100 (11.4)		201 (12.3)	94 (13.5)	107 (11.4)		
2	28 (2.1)	11 (2.4)	17 (1.9)		47 (2.9)	23 (3.3)	24 (2.6)		
ICAS				< .001				.37	.51
No	784 (58.4)	240 (51.5)	537 (61.3)		928 (56.8)	374 (53.7)	536 (57.1)		
Yes	521 (38.8)	200 (42.9)	318 (36.3)		667 (40.8)	297 (42.6)	369 (39.3)		
TOAST Classification				.13				.04	.16
LAA	386 (28.8)	140 (30)	246 (28.1)		513 (31.4)	233 (33.4)	280 (29.9)		
SVO	643 (47.9)	204 (43.8)	439 (50.1)		726 (44.4)	281 (40.3)	445 (47.4)		

OE	26 (1.9)	11 (2.4)	15 (1.7)		24 (1.5)	11 (1.6)	13 (1.4)		
UD	287 (21.4)	111 (23.8)	176 (20.1)		372 (22.8)	172 (24.7)	200 (21.3)		
New infarct *	693 (51.6)	264 (56.7)	429 (49)	.005	949 (58.0)	433 (62.1)	516 (55.0)	<.001	.001
Laboratory findings ((Mean ± SD)									
LDL, mmol/L	2.6 ± 0.8	65.3 ± 34.7	33.8 ± 32.3	<.001	2.6 ± 0.8	67.0 ± 34.5	34.3 ± 32.1	<.001	.048
TC, mmol/L	4.2 ± 1.1	2.5 ± 0.8	2.6 ± 0.8	.33	4.2 ± 1.1	2.6 ± 0.9	2.6 ± 0.8	.43	.71
HCY, μmol/L	23.1 ± 18.6	4.1 ± 1.1	4.2 ± 1.1	.27	24.6 ± 23.0	4.2 ± 1.1	4.2 ± 1.1	.39	.048
Cr, μmol/L	74.7 ± 35.3	22.4 ± 17.6	23.5 ± 19.1	.32	74.9 ± 35.1	24.3 ± 23.3	24.9 ± 22.7	.64	.86
Urea, mmol/L	5.4 ± 2.4	76.4 ± 36.3	73.8 ± 34.7	.19	5.7 ± 15.1	76.7 ± 46.3	73.6 ± 23.6	.07	.39
INR	1.1 ± 0.4	5.5 ± 2.2	5.4 ± 2.5	.37	1.1 ± 0.4	5.5 ± 2.0	5.9 ± 19.9	.56	.82
PLT, 109/L	217.4 ± 60.3	1.1 ± 0.2	1.1 ± 0.5	.74	217.5 ± 64.7	1.1 ± 0.5	1.1 ± 0.4	.69	.97
WBC, 109/L	7.1 ± 2.1	210.7 ± 62.8	221.1 ± 58.7	.003	7.1 ± 2.2	217.3 ± 67.9	217.7 ± 62.3	.87	.92

Abbreviations: AF, atrial fibrillation; BMI, body mass index; CAD, coronary artery disease; C-A, clopidogrel-aspirin; Cr, creatinine; DBP, diastolic blood pressure; ESRS, Essen stroke risk score; GU, gastric ulcer; HCY, homocysteine; LAA, large-artery atherosclerosis; LDL, low-density lipoprotein; MI, myocardial infarction; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OE, stroke of other determined etiology; PAD, peripheral artery disease; PLT, platelet; ICAS, intracranial atherosclerosis; ICH, intracranial hemorrhage; IS, ischemic stroke; INR, international standardized ratio; SBP, systolic blood pressure; SVO, small-vessel occlusion; TC, total cholesterol; TIA, transient ischemic attack; TOAST, Trial of Org 10172 in Acute Stroke Treatment; UD, stroke of undetermined etiology; and WBC, white blood cell.

*Indicated the image (CT or MRI) before using antiplatelet combined with statin.

**Indicated the patients with NIHSS between 4 to 5 point and onset within 72 hours, and patients with NIHSS between 0 to 5 points and onset within 24-72 hours.

#Indicated comparison the general characteristics between SAPT and DAPT groups.

†Indicated comparison the general characteristics between like-RCT population and no-RCT eligibility population.

7

sTable 16. General Characteristics of Dual Antiplatelet Therapy (C-A) and Single Antiplatelet in Patients with Standard Duration and no-RCT** Eligibility.			
	Crude	IPTW	PSM

Characteristics	SAPT	DAPT	P value#	ASD†	SAPT	DAPT	P value#	ASD†	SAPT	DAPT	P value#	ASD†
N, (Mean ± SD)/%	697	491			768	297			195	195		
Age, y	64.8 ± 13.0	58.9 ± 11.1	<.001	.48	61.4±13.6	60.5± 11.3	.09	.07	63.8±13.4	59.0±11.6	<.001	.38
Male	476 (68.3)	380 (77.4)	<.001	.20	561(73.0)	220 (73.9)	.73	.02	134(68.7)	152(77.9)	.04	.21
BMI, kg/m^2	24.4 ± 3.3	25.4 ± 3.5	<.001	.28	24.8± 3.6	25.0± 3.4		.07	24.3± 3.7	25.3± 3.9	.01	.26
SBP, mmHg	151.0± 22.3	154.9± 21.7	.003	.17	153.0±22.1	153.3±21.5		.01	149.9±21.0	153.4±20.7	.09	.17
DBP, mmHg	86.8± 13.9	90.1 ± 13.8	<.001	.23	88.3±15.2	88.8±13.4		.04	85.9±14.6	89.6±13.2	.01	.26
Smoking, n (%)			<.001	.32			.36	.07			.36	.18
Never	386 (55.4)	206 (42)			373 (48.6)	135 (45.4)			98 (50.3)	86 (44.1)		
Previous	43 (6.2)	21 (4.3)			37 (4.8)	13 (4.5)			10 (5.1)	6 (3.1)		
Current	249 (35.7)	251 (51.1)			337 (43.9)	140 (47.1)			81 (41.5)	97 (49.7)		
Medical history, no. (%)												
Hypertension	428 (61.4)	294 (59.9)	.59	.03	458 (59.7)	178 (60.0)	.93	.006	113 (57.9)	111 (56.9)	.84	.02
Diabetes	194 (27.8)	129 (26.3)	.55	.04	201 (26.1)	75 (25.2)	.76	.02	46 (23.6)	44 (22.6)	.81	.02
Dyslipidemia	15 (2.2)	7 (1.4)	.36	.07	12 (1.6)	4 (1.5)	.79	.008	4 (2.1)	5 (2.6)	1.00	.03
Atrial fibrillation	4 (0.6)	2 (0.4)	1.00	.02	4 (0.5)	2 (0.6)	.77	.01	2 (1.0)	0 (0.0)	.50	.14
TIA	13 (1.9)	7 (1.4)	.56	.02	12 (1.5)	5 (1.7)	.89	.01	5 (2.6)	4 (2.1)	1.00	.03
Previous IS	185 (26.5)	94 (19.1)	.003	.18	181 (23.6)	62 (20.8)	.35	.07	45 (23.1)	28 (14.4)	.03	.22
PAD	7 (1)	1 (0.2)	.15	.10	5 (0.6)	1 (0.3)	.54	.05	1 (0.5)	0 (0.0)	1	.10
MI	13 (1.9)	8 (1.6)	.76	.02	10 (1.3)	4 (1.5)	.95	.02	3 (1.5)	1 (0.5)	.62	.10
CAD	46 (6.6)	29 (5.9)	.63	.02	43 (5.5)	17 (5.8)	.94	.01	12 (6.2)	10 (5.1)	.66	.04
ICH	22 (3.2)	6 (1.2)	.03	.13	16 (2.1)	4 (1.5)	.43	.047	3 (1.5)	4 (2.1)	1	.04
GU	12 (1.7)	3 (0.6)	.09	.10	9 (1.1)	3 (1.0)	.82	.01	4 (2.1)	1 (0.5)	.37	.14
Medication history, n (%)												

Antiplatelet	71 (10.2)	48 (9.8)	.94	.01	87 (11.3)	29 (9.7)	.46	.05	18 (9.2)	19 (9.7)	.86	.10
Anti-hypertensive	293 (42)	187 (38.1)	.19	.11	308 (40.2)	114 (38.3)	.61	.048	72 (36.9)	70 (35.9)	.92	.04
Statins	48 (6.9)	32 (6.5)	.97	.02	56 (7.4)	19 (6.4)	.61	.046	13 (6.7)	11 (5.6)	.67	.04
Anti-diabetes	145 (20.8)	83 (16.9)	.14	.12	149 (19.4)	51 (17.1)	.40	.09	33 (16.9)	26 (13.3)	.26	.17
Antiplatelet days	67.0 ± 34.5	17.6 ± 3.8	<.001	2.02	41.6 ±37.8	17.8±3.7	<.001	.89	14.9±9.7	20.7±1.5	<.001	.83
Strength statin	361 (51.9)	301 (61.7)	.69	.20	443 (57.8)	184 (62.1)	.20	.09	124 (63.6)	140 (71.8)	.08	.18
Clinical evaluation, n (%)												
Baseline NIHSS score			.13	.08			.11	.08			.29	.11
0-3 points	482 (69.2)	319 (65)			520 (67.7)	280 (64.1)			120 (61.5)	130 (66.7)		
4-5 points	215 (30.8)	172 (35)			248 (32.3)	107 (35.9)			75 (38.5)	65 (33.3)		
Onset to arrival time			.08	.09			.42	.054			.39	.09
0-24 hr	127 (18.2)	110 (22.4)			156 (20.2)	67 (22.4)			45 (23.1)	38 (19.5)		
24-72 hr	570 (81.8)	381 (77.6)			612(79.8)	230 (77.6)			150 (76.9)	157 (80.5)		
Pre-mRs			.06	.14			.52	.049			.55	.11
0	580 (83.2)	433 (88.2)			658 (85.7)	259 (87.4)			166 (85.1)	173 (88.7)		
1	94 (13.5)	47 (9.6)			92 (12.0)	31 (10.5)			24 (12.3)	18 (9.2)		
2	23 (3.3)	11 (2.2)			18 (2.3)	6 (2.2)			5 (2.6)	4 (2.1)		
ICAS			.046	.16			.93	.04			.63	.10
No	374 (53.7)	299 (60.9)			458 (59.7)	178 (59.8)			113 (57.9)	121 (62.1)		
Yes	297 (42.6)	177 (36)			275 (35.9)	108 (36.5)			75 (38.5)	66 (33.8)		
TOAST Classification			.03	.18			.35	.12			.61	.14
LAA	233 (33.4)	128 (26.1)			229 (29.9)	80 (26.8)			53 (27.2)	51 (26.2)		
SVO	281 (40.3)	232 (47.3)			311 (40.5)	131 (44.1)			81 (41.5)	83 (42.6)		
OE	11 (1.6)	6 (1.2)			10 (1.3)	7 (2.4)			7 (3.6)	3 (1.5)		
UD	172 (24.7)	125 (25.5)			217 (28.3)	79 (26.7)			54 (27.7)	58 (29.7)		
New infarct *	433 (62.1)	280 (57)	.11	.12	463 (60.3)	177 (59.7)	.84	.06	122 (62.6)	120 (61.5)	.83	.11
Laboratory findings ((Mean ± SD)												
LDL, mmol/L	2.6 ± 0.9	2.6 ± 0.8	.84	.008	2.6±0.82	2.6± 0.81	.68	.06	2.6±0.80	2.6±0.8	.82	.02

TC, mmol/L	4.2 ± 1.1	4.2 ± 1.0	.57	.03	4.1±1.1	4.2±1.1	.42	.048	4.2±1.1	4.1±1.1	.58	.06
HCY, μmol/L	24.3 ± 23.3	24.1 ± 19.9	.86	.01	23.7±21.6	23.9±20.0	.95	.009	24.4±21.3	23.3±18.5	.58	.06
Cr, μmol/L	76.7 ± 46.3	73.6 ± 17.5	.16	.09	75.4±35.7	74.3±18.6	.73	.04	74.5±18.5	73.8±18.6	.70	.04
Urea, mmol/L	5.5 ± 2.0	5.3 ± 1.7	.06	.10	5.4±1.9	5.4±1.8	.79	.03	5.5±1.8	5.3±1.5	.22	.13
INR	1.1 ± 0.5	1.1 ± 0.5	.95	.006	1.1±0.4	1.1±0.4	.80	.02	1.1±0.1	1.1± 0.1	.62	.05
PLT, 109/L	217.3±67.9	214.2± 60.3	.42	.05	216.2±63.9	216.7±70.4	.92	.008	214.3±66.4	215.1±62.1	.90	.01
WBC, 109/L	7.1 ± 2.1	7.1 ± 2.1	.79	.02	7.1± 2.1	7.2± 2.2	.73	.04	7.1±2.2	7.2± 2.2	.69	.04

Abbreviations: AF, atrial fibrillation; ASD, absolute standardized difference; BMI, body mass index; CAD, coronary artery disease; C-A, clopidogrel-aspirin; Cr, creatinine; DBP, diastolic blood pressure; ESRS, Essen stroke risk score; GU, gastric ulcer; HCY, homocysteine; LAA, large-artery atherosclerosis; LDL, low-density lipoprotein; MI, myocardial infarction; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OE, stroke of other determined etiology; PAD, peripheral artery disease; PLT, platelet; ICAS, intracranial atherosclerosis; ICH, intracranial hemorrhage; IS, ischemic stroke; INR, international standardized ratio; SBP, systolic blood pressure; SVO, small-vessel occlusion; TC, total cholesterol; TIA, transient ischemic attack; TOAST, Trial of Org 10172 in Acute Stroke Treatment; UD, stroke of undetermined etiology; and WBC, white blood cell.
*Indicated the image (CT or MRI) before using antiplatelet combined with statin.
**Indicated the patients with NIHSS between 4 to 5 point and onset within 72 hours, and patients with NIHSS between 0 to 5 points and onset within 24-72 hours.
#P values were calculated using Pearson $\chi 2$ test, Fisher exact test, Student t test, or the Wilcoxon rank-sum test, as appropriate.
†An ASD of >0.1 is considered a meaningful imbalance.

sTable 17 Efficacy and Safety Outcome Event Rates* of Single Antiplatelet Therapy and Dual Antiplatelet Therapy with Aspirin-Clopidogrel in Patients with Standard Duration and no-RCT** Eligibility.

	Crude			IPTW			PSM		
	SAPT	DAPT	P value†	SAPT	DAPT	P value‡	SAPT	DAPT	P value
Primary outcome									
No. of events	57	29		74	16		21	6	

90 days event rate (95CI%), %	8.2(6.1-10.2)	5.9(3.8-8.0)	.14	9.6(7.5-11.7)	5.4(2.8-8.0)	.03	10.8(6.4-15.2)	3.1(0.6-5.5)	.003
Secondary outcome									
Ischemic stroke									
No. of events	47	22		65	12		18	4	
90 days event rate (95CI%), %	6.7(4.9-8.6)	4.5(2.6-6.3)	.10	8.5(6.5-10.4)	4.0(1.8-6.3)	.01	9.2(5.1-13.3)	2.1(0.0-4.1)	.002
TIA									
No. of events	5	3		-	-		1	1	
90 days event rate (95CI%), %	0.7(0.1-1.3)	0.6(-0.1-1.3)	.83	-	-		0.5(-0.5-1.5)	0.5(0.6-5.5)	1
s-ICH									
No. of events	2	1		-	-		0	0	
90 days event rate (95CI%), %	0.3(-0.1-0.7)	0.2(-0.2-0.6)	.78	-	-		0	0	1
Myocardial infarction									
No. of events	1	2		-	-		0	1	
90 days event rate (95CI%), %	0.1(-0.1-0.4)	0.4(-0.2-1.0)	.37	-	-		0	0.5(-0.5-1.5)	1
Death									
No. of events	2	1		-	-		2	0	
90 days event rate (95CI%), %	0.3(-0.1-0.7)	0.2(-0.2-0.6)	.78	-	-		1.0(-0.4-2.5)	0	.50
Safety outcome									
Sever bleeding									
No. of events	2	1		-	-		0	0	
90 days event rate (95CI%), %	0.3(-0.1-0.7)	0.2(-0.2-0.6)	.78	-	-		0	0	1
All intracranial hemorrhage									

No. of events	21	6		16	5		4	2	
90 days event rate (95CI%), %	3.0(1.7-4.3)	1.2(0.2-2.2)	.04	2.1(1.1-3.1)	1.7(0.2-3.2)	.67	2.1(0.0-4.1)	2.1(-0.4-2.5)	.69
Any bleeding									
No. of events	49	33		38	19		11	15	
90 days event rate (95CI%), %	7.0(5.1-8.9)	6.7(4.5-8.9)	.84	4.9(3.4-6.5)	6.4(3.6-9.2)	.35	5.7(2.4-8.9)	7.7(3.9-11.5)	.44

Abbreviations: CI, Confidence interval; DAPT, dual antiplatelet therapy; IPTW, inverse probability of treatment weighting; PSM, propensity score matching; SAPT, single antiplatelet therapy; s-ICH, Symptomatic intracranial hemorrhage and TIA, Transient ischemic attack.
*Event rates were derived from Kaplan-Meier curves.
**Indicated the patients with NIHSS between 4 to 5 point and onset within 72 hours, and patients with NIHSS between 0 to 5 points and onset within 24-72 hours.
†P values calculated using log-rank tests.
‡P values calculated using IPTW log-rank tests.
§P values calculated using stratified log-rank tests.

sTable 18 HRs of Dual Antiplatelet Therapy Compared Single Antiplatelet Therapy According to the Analytical Methods Used in Patients with Standard Duration and no-RCT** Eligibility.

	Crude		Adjusted*		IPTW		PSM	
	HR (95%CI)†	P value	HR (95%CI)†	P value	HR (95%CI) ‡	P value	HR (95%CI) §	P value
Primary outcome								
DAPT (vs. SAPT)	0.63 (0.4~1)	.051	0.52 (0.28~0.94)	.03	0.54 (0.31~0.93)	.03	0.23 (0.09~0.61)	.003
Secondary outcome								
Ischemic stroke								
DAPT (vs. SAPT)	0.58 (0.34~0.98)	.04	0.42 (0.21~0.83)	.01	0.47 (0.25~0.87)	.02	0.16 (0.05~0.54)	.003
TIA								
DAPT (vs. SAPT)	0.85 (0.2~3.57)	.83	2 (0.2~19.69)	.55	-	-	1 (0.06~16.03)	1.00

s-ICH								
DAPT (vs. SAPT)	0.71 (0.06~7.83)	.78	7.76 (0~Inf)	.74	-	-	-	-
AM								
DAPT (vs. SAPT)	2.84 (0.26~31.34)	.39	4.62 (0.06~384.3)	.49	-	-	Inf(0~Inf)	1.00
Death								
DAPT (vs. SAPT)	0.71 (0.06~7.83)	.78	Inf(0~Inf)	.79	-	-	0.42 (0~Inf)	1.00
Safety outcome								
Sever bleeding								
DAPT (vs. SAPT)	0.71 (0.06~7.83)	.78	7.76 (0~Inf)	.74	-	-	-	-
All ICH								
DAPT (vs. SAPT)	0.4 (0.16~0.99)	.048	0.68 (0.19~2.47)	.56	0.73 (0.26~2.08)	.56	0.5 (0.09~2.73)	.42
Any bleeding								
DAPT (vs. SAPT)	0.95 (0.61~1.47)	.81	1.06 (0.55~2.04)	.87	1.41 (0.83~2.38)	.20	1.33 (0.61~2.89)	.48

Abbreviations: CI, Confidence interval; DAPT, dual antiplatelet therapy; IPTW, inverse probability of treatment weighting; PSM, propensity score matching; SAPT, single antiplatelet therapy; s-ICH, Symptomatic intracranial hemorrhage and TIA, Transient ischemic attack.
*Adjusted for the variables listed in Table S10.
**Indicated the patients with NIHSS between 4 to 5 point and onset within 72 hours, and patients with NIHSS between 0 to 5 points and onset within 24-72 hours.
†Conventional Cox proportional hazards models.
‡Weighted Cox proportional hazards models.
§Cox proportional hazards models within matched pairs.

sTable 19 General Characteristics of Patients Stratified by Long-Term Secondary Treatment.				
Characteristics	AM	CM	DAPT	P value*

N	2074	359	470	
Age, y (Mean ± SD)	61.0 ± 11.8	66.4 ± 11.8	60.6 ± 11.5	< .001
Male	1552 (74.8)	239 (66.6)	342 (72.8)	.004
BMI, kg/m^2 (Mean ± SD)	25.0 ± 3.5	24.2 ± 3.4	24.9 ± 4.0	< .001
SBP, mmHg (Mean ± SD)	153.0 ± 21.4	153.3 ± 23.1	152.1 ± 23.0	.66
DBP, mmHg (Mean ± SD)	89.3 ± 13.6	85.9 ± 13.4	86.9 ± 14.1	<.001
Smoking, n (%)				.001
Never	967 (46.6)	210 (58.5)	205 (43.6)	
Previous	124 (6)	19 (5.3)	32 (6.8)	
Current	923 (44.5)	119 (33.1)	220 (46.8)	
Medical history, no. (%)				
Hypertension	1256 (60.6)	223 (62.1)	283 (60.2)	.83
Diabetes	536 (25.8)	107 (29.8)	127 (27)	.28
Dyslipidemia	49 (2.4)	7 (1.9)	10 (2.1)	.87
AF	11 (0.5)	1 (0.3)	2 (0.4)	1.00
TIA	33 (1.6)	6 (1.7)	10 (2.1)	.72
Previous IS	435 (21)	97 (27)	113 (24)	.02
PAD	17 (0.8)	2 (0.6)	5 (1.1)	.79
MI	29 (1.4)	6 (1.7)	10 (2.1)	.50
CAD	97 (4.7)	30 (8.4)	34 (7.2)	.004
ICH	45 (2.2)	12 (3.3)	6 (1.3)	.13
GU	9 (0.4)	18 (5)	6 (1.3)	<.001
Medication history, n (%)				
Antiplatelet	208 (10)	44 (12.3)	73 (15.5)	.007
Anti-hypertensive	832 (40.1)	163 (45.4)	205 (43.6)	.25
Statins	130 (6.3)	35 (9.7)	51 (10.9)	.004
Anti-diabetes	393 (18.9)	76 (21.2)	106 (22.6)	<.001
Antiplatelet days	40.9±34.6	43.7±38.4	79.4±27.2	<.001
Duration of DAPT				<.001
Shorter (10 days)	221 (18.0)	53 (31.6)	28 (6.1)	

Standard (10-21 days)	796 (64.7)	81 (45.8)	21 (4.6)	
Longer (21 days)	213 (17.3)	40(22.6)	407 (89.3)	
Antiplatelet at admission				<.001
SAPT	844 (40.7)	182 (50.7)	102 (21.7)	
DAPT	1230 (59.3)	177 (49.3)	368 (78.3)	
Strength statin at admission	1243(60.2)	177(49.3)	310(66.5)	<.001
Clinical evaluation, n (%)				
Duration of hospital	11.9±8.1	12.3±4.8	13.8±34.4	.23
Baseline NIHSS score				.18
0-3 points	1696 (81.8)	292 (81.3)	370 (78.7)	
4-5 points	378 (18.2)	67 (18.7)	100 (21.3)	
Onset to arrival time				.42
0-24 hr	1163 (56.1)	198 (55.2)	271 (57.7)	
24-72 hr	911 (43.9)	161 (44.8)	199 (42.3)	
Pre-mRs				.008
0	1804 (87)	289 (80.5)	389 (82.9)	
1	225 (10.8)	60 (16.7)	67 (14.3)	
2	45 (2.2)	10 (2.8)	13 (2.8)	
ICAS				<.001
No	1224 (59)	203 (56.5)	224 (47.7)	
Yes	778 (37.5)	137 (38.2)	235 (50)	
TOAST Classification				<.001
LAA	570 (27.5)	100 (27.9)	203 (43.2)	
SVO	988 (47.6)	167 (46.5)	185 (39.4)	
OE	31 (1.5)	8 (2.2)	8 (1.7)	
UD	485 (23.4)	84 (23.4)	74 (15.7)	
Laboratory findings ((Mean ± SD)				
LDL, mmol/L	2.6 ± 0.8	2.6 ± 0.8	2.6 ± 0.9	.48
TC, mmol/L	4.2 ± 1.0	4.2 ± 1.1	4.2 ± 1.2	.85

HCY, μmol/L	24.3 ± 22.0	23.1 ± 19.8	23.3 ± 19.1	.49
Cr, μmol/L	75.3 ± 37.6	76.1 ± 35.4	72.1 ± 23.3	.16
Urea, mmol/L	5.4 ± 2.2	5.4 ± 2.0	6.6 ± 28.1	.09
INR	1.1 ± 0.5	1.1 ± 0.2	1.1 ± 0.1	.55
PLT, 109/L	216.7 ± 60.2	215.0 ± 75.9	223.6 ± 63.2	.07
WBC, 109/L	7.1 ± 2.1	6.9 ± 2.2	7.4 ± 2.5	<.001

Abbreviations: AF, atrial fibrillation; AM, aspirin monotherapy; BMI, body mass index; CAD, coronary artery disease; CM, clopidogrel monotherapy; Cr, creatinine; DBP, diastolic blood pressure; ESRS, Essen stroke risk score; GU, gastric ulcer; HCY, homocysteine; LAA, large-artery atherosclerosis; LDL, low-density lipoprotein; MI, myocardial infarction; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OE, stroke of other determined etiology; PAD, peripheral artery disease; PLT, platelet; ICAS, intracranial atherosclerosis; ICH, intracranial hemorrhage; IS, ischemic stroke; INR, international standardized ratio; SBP, systolic blood pressure; SVO, small-vessel occlusion; TC, total cholesterol; TIA, transient ischemic attack; TOAST, Trial of Org 10172 in Acute Stroke Treatment; UD, stroke of undetermined etiology; and WBC, white blood cell.
*P values were calculated using through Pearson χ2 test, Fisher exact test and ANOVA.

sTable 20 General Characteristics of Patients Stratified by Different Dose of Antiplatelet Therapy.

	DAPT		SAPT				
Characteristics	DAPT-ALC	DAPT-AUC	AM	CM	P*	P**	P***
N	1170	644	961	202			
Age, y (Mean ± SD)	58.6 ± 10.6	61.7 ± 11.3	64.1 ± 12.6	68.7 ± 12.2	< .001	<.001	<.001
Male	905 (77.4)	470 (73)	670 (69.7)	138 (68.3)	.04	.69	<.001
BMI, kg/m^2 (Mean ± SD)	25.2 ± 3.3	24.9 ± 3.6	24.7 ± 3.6	23.8 ± 3.3	.12	.002	<.001
SBP, mmHg (Mean ± SD)	153.1 ± 20.8	154.1 ± 23.2	152.2 ± 22.2	151.3 ± 22.6	.39	.61	.27
DBP, mmHg (Mean ± SD)	89.7 ± 13.2	88.7 ± 14.4	87.4 ± 13.7	84.8 ± 13.8	.17	.02	<.001
Smoking, n (%)					.002	.09	<.001
Never	478 (40.9)	324 (50.3)	495 (51.5)	123 (60.9)			
Previous	76 (6.5)	35 (5.4)	59 (6.1)	12 (5.9)			

Current	582 (49.7)	270 (41.9)	372 (38.7)	62 (30.7)			
Medical history, no. (%)							
Hypertension	689 (58.9)	389 (60.4)	605 (63)	121 (59.9)	.53	.42	.29
Diabetes	295 (25.2)	172 (26.7)	269 (28)	56 (27.7)	.49	.94	.52
Dyslipidemia	32 (2.7)	13 (2)	22 (2.3)	2 (1)	.35	.41	.49
AF	1 (0.1)	4 (0.6)	9 (0.9)	2 (1)	.06	1	.02
TIA	25 (2.1)	7 (1.1)	17 (1.8)	0 (0)	.10	.06	.08
Previous IS	221 (18.9)	144 (22.4)	240 (25)	71 (35.1)	.08	.003	<.001
PAD	10 (0.9)	3 (0.5)	8 (0.8)	3 (1.5)	.40	.42	.49
MI	14 (1.2)	12 (1.9)	18 (1.9)	4 (2)	.25	1	.47
CAD	50 (4.3)	41 (6.4)	51 (5.3)	22 (10.9)	.05	.003	.001
ICH	12 (1)	10 (1.6)	31 (3.2)	11 (5.4)	.33	.12	<.001
GU	8 (0.7)	4 (0.6)	11 (1.1)	11 (5.4)	1	<.001	<.001
Medication history, n (%)							
Antiplatelet	124 (10.6)	71 (11)	113 (11.8)	28 (13.9)	.74	0.53	.61
Anti-hypertensive	462 (39.5)	269 (41.8)	408 (42.5)	91 (45)	.29	.56	.59
Statins	75 (6.4)	51 (7.9)	72 (7.5)	26 (12.9)	.43	.045	.045
Anti-diabetes	218 (18.6)	125 (19.4)	207 (21.5)	41 (20.3)	.81	.29	.51
Antiplatelet days	34.1 ± 31.5	34.1 ± 33.5	66.6 ± 34.4	64.9 ± 35.6	.966	.52	<.001
Strength statin at admission	905 (77.7)	283 (44.3)	499 (52.2)	74 (37.2)	< .001	<.001	<.001
Clinical evaluation, n (%)							
Baseline NIHSS score					.01	.54	.07
0-3 points	964 (82.4)	500 (77.6)	779 (81.1)	169 (83.7)			
4-5 points	206 (17.6)	144 (22.4)	182 (18.9)	33 (16.3)			
Onset to arrival time					.66	.12	<.001
0-24 hr	699 (59.7)	378 (58.7)	480 (49.9)	113 (55.9)			
24-72 hr	471 (40.3)	266 (41.3)	481 (50.1)	89 (44.1)			
Pre-mRs					<.001	.003	<.001
0	1040 (89)	525 (81.5)	815 (84.8)	153 (75.7)			

1	102 (8.7)	105 (16.3)	123 (12.8)	38 (18.8)			
2	27 (2.3)	14 (2.2)	23 (2.4)	11 (5.4)			
ICAS					.12	.44	.003
No	680 (58.1)	393 (61)	513 (53.4)	101 (50)			
Yes	460 (39.3)	227 (35.2)	408 (42.5)	89 (44.1)			
TOAST Classification					.05	.91	.005
LAA	331 (28.3)	195 (30.3)	305 (31.7)	68 (33.7)			
SVO	555 (47.4)	329 (51.1)	400 (41.6)	85 (42.1)			
OE	19 (1.6)	9 (1.4)	19 (2)	3 (1.5)			
UD	265 (22.6)	111 (17.2)	237 (24.7)	46 (22.8)			
New infarct#	610 (52.1)	335 (52)	580 (60.4)	117 (57.9)	.75	.63	<.001
Laboratory findings ((Mean ± SD)							
LDL, mmol/L	2.7 ± 0.8	2.5 ± 0.8	2.6 ± 0.9	2.5 ± 0.8	<.001	.02	<.001
TC, mmol/L	4.3 ± 1.1	4.1 ± 1.1	4.2 ± 1.1	4.0 ± 1.1	.003	.07	.003
HCY, μmol/L	24.2 ± 21.4	24.1 ± 20.4	24.0 ± 21.7	21.6 ± 18.9	.93	.14	.42
Cr, μmol/L	74.3 ± 26.6	72.5 ± 34.1	75.4 ± 31.1	82.3 ± 76.2	.22	.04	.006
Urea, mmol/L	5.3 ± 2.1	6.3 ± 24.0	5.4 ± 1.9	5.7 ± 2.9	.17	.15	.34
INR	1.1 ± 0.4	1.1 ± 0.4	1.1 ± 0.5	1.1 ± 0.1	.81	.82	.99
PLT, 109/L	217.8 ± 60.0	222.1 ± 61.5	214.3 ± 63.1	216.1 ± 78.5	.14	.73	.11
WBC, 109/L	7.2 ± 2.2	7.1 ± 1.9	7.1 ± 2.1	7.0 ± 2.4	.47	.57	.763

Abbreviations: AF, atrial fibrillation; AM, aspirin monotherapy; BMI, body mass index; CAD, coronary artery disease; CM, clopidogrel monotherapy; Cr, creatinine; DAPT-ALC, patients used dual antiplatelet therapy with aspirin and loading clopidogrel (clopidogrel loading dose of 300 mg on the first day); DAPT-AUC, dual antiplatelet therapy with aspirin and no loading clopidogrel (clopidogrel 75 mg daily with no loading dose); DBP, diastolic blood pressure; ESRS, Essen stroke risk score; GU, gastric ulcer; HCY, homocysteine; LAA, large-artery atherosclerosis; LDL, low-density lipoprotein; MI, myocardial infarction; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OE, stroke of other determined etiology; PAD, peripheral artery disease; PLT, platelet; ICAS, intracranial atherosclerosis; ICH, intracranial hemorrhage; IS, ischemic stroke; INR, international standardized ratio; SBP, systolic blood pressure; SVO, small-vessel occlusion; TC, total cholesterol; TIA, transient ischemic attack; TOAST, Trial of Org 10172 in Acute Stroke Treatment; UD, stroke of undetermined etiology; and WBC, white blood cell.
#Indicated the image (CT or MRI) before using antiplatelet drugs.

*Comparison of baseline data between the DAPT-ALC and DAPT-AUC groups；
**Comparison of baseline data between the AM and CM groups； all calculated using Pearson χ2 test, Fisher exact test, Student t test, or the Wilcoxon rank-sum test, as appropriate.
***Comparison of baseline data among four groups and calculated using through Pearson χ2 test, Fisher exact test and ANOVA.